[
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$cPmzjrONlsziodDHXHNqk2$fvkZYUaYqWa2pfTxFmYjbtgY9n8NiBgQDQ5Wzy49Luw=",
      "last_login": "2025-12-01 22:55:49.242173",
      "is_superuser": 1,
      "username": "Nick",
      "first_name": "",
      "last_name": "",
      "is_staff": 1,
      "is_active": 1,
      "date_joined": "2025-06-05 11:13:53.180298",
      "role": "",
      "email": "Nick@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$ENkhm3KlMGWAUrbirgyVhQ$e8W2tHwrgxeyc3nIWQueKHTsIVdlTAW2rAKp14jOMgY=",
      "last_login": "2025-08-14 11:05:12.257977",
      "is_superuser": 0,
      "username": "CVS_pharm",
      "first_name": "CVS",
      "last_name": "Pharm",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-05 11:18:59",
      "role": "pharmacy admin",
      "email": "cvs@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$QgY39KRXAnQEPag2P14neJ$UlNbwc0dBYTPPbcGDE+EY3je8ZZWvI3bG1TWugE8XTU=",
      "last_login": "2025-08-14 17:17:33.143124",
      "is_superuser": 0,
      "username": "RightAide_pharm",
      "first_name": "Right Aide",
      "last_name": "Pharm",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-05 11:32:09",
      "role": "pharmacy admin",
      "email": "rightaide@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$uaEmEYdTjixs84XSXmnUqU$nyLO4FNglvL707YH6q/7Mv+JckKfcv9pPheAH/o+1UU=",
      "last_login": "2025-08-14 17:17:09.400084",
      "is_superuser": 0,
      "username": "ngeorge",
      "first_name": "Nick",
      "last_name": "George",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-05 11:45:30",
      "role": "pharmacist",
      "email": "ngeorge@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$qqJKog2UTCHOKexgbd84zb$JKsTg7nGIGCVB0n1UmhMBvEAoFOYXdgh4KQMWNznnFQ=",
      "last_login": "2025-07-16 11:48:48.471246",
      "is_superuser": 0,
      "username": "rsmith",
      "first_name": "Rod",
      "last_name": "Smith",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-05 12:10:56",
      "role": "pharmacist",
      "email": "rsmith25@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$0fWzdohWR2b54beOhbpt9s$74JvMp8bkA8afUbUCM838PAKtGI30JykVlrW5bYQkO4=",
      "last_login": "2026-01-03 13:04:53.236289",
      "is_superuser": 0,
      "username": "jjackson",
      "first_name": "Justin",
      "last_name": "Jackson",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-05 12:28:43",
      "role": "patient",
      "email": "jjackson@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$ocBo1fWPqwUs2KX5zkfh8d$/N7hOPKzuW9q1KuYDHHMcNJrPr81UgXix35KGyDrkAs=",
      "last_login": "2026-01-05 20:38:49.702613",
      "is_superuser": 0,
      "username": "woodlands_pharm",
      "first_name": "woodlands",
      "last_name": "pharmacy",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 10:31:32",
      "role": "pharmacy admin",
      "email": "woodlands@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$RaQH0gTPl2QaLDd2T6mN1j$6/neAUUP5x/pnJ6ig2VWexA3Ff0mTr/1uLd2nlfhauc=",
      "last_login": "2026-01-02 22:19:05.614658",
      "is_superuser": 0,
      "username": "marshallgroup_pharm",
      "first_name": "marshallgroup",
      "last_name": "pharmacy",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 10:31:48",
      "role": "pharmacy admin",
      "email": "marshallgroup@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ffDp5zYB6hCkOlqbBnNuTw$pSlfdJVnqXO0mhPSFdYDo6u/8o70lYxaLD/gP2iQCek=",
      "last_login": null,
      "is_superuser": 0,
      "username": "wallbrowns_pharm",
      "first_name": "wallbrowns",
      "last_name": "pharmacy",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 10:32:05",
      "role": "pharmacy admin",
      "email": "wallbrowns@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$YdUzW1QGzGlHvS8Xf2J7mQ$WU4IoJIQGFVMEN5oRzSSep/OewE2ro9SAG6BbhytZBs=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rnavarro",
      "first_name": "Randall",
      "last_name": "Navarro",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:35.841442",
      "role": "pharmacist",
      "email": "rnavarro@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$IFgX6jjv5K9JOOtdjoO9TU$pRfJcouSQta6nRVAuG7iyDqPrXUPPWgkuOwhiRICNlI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cjones",
      "first_name": "Christina",
      "last_name": "Jones",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:36.468988",
      "role": "pharmacist",
      "email": "cjones@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$1bZ1AYx4DHXIdBTsGvjn51$Il9vTk2GI0jq/OvN5I/dkcfBb6mRqjFG4F/oVcNFdH0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rrichmond",
      "first_name": "Richard",
      "last_name": "Richmond",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:36.896154",
      "role": "pharmacist",
      "email": "rrichmond@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$qkRdPMhAiCGZAlUg0Zgehc$fI7ho86Dq6Y9RN0GMMaUlRKXyLaGXut8KQA3Ht50+wo=",
      "last_login": null,
      "is_superuser": 0,
      "username": "acamacho",
      "first_name": "Andrea",
      "last_name": "Camacho",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:37.355272",
      "role": "patient",
      "email": "acamacho@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$59cVSNCXnmyVdJD2liAXYq$64unD7RyD83yI8c7aUasbDY4vdg1fuEvQxfubzX/XKg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jprice",
      "first_name": "Jordan",
      "last_name": "Price",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:37.779164",
      "role": "patient",
      "email": "jprice@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$v7wFRpYSd2F8A16qXhqLsG$aLCsTxtb/aeYyQLq/csxFNnWXuE8OIs+18z71WbmsUw=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jmoore",
      "first_name": "Jodi",
      "last_name": "Moore",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:38.204877",
      "role": "patient",
      "email": "jmoore@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$qH7hqgvrj2wLCcSo6Qdhcf$OfgwZ+OBK2IUXW9qf/h3fafrc/suZCpv9ljRrkeUWTg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mperez",
      "first_name": "Mark",
      "last_name": "Perez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:38.656820",
      "role": "patient",
      "email": "mperez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$LnomslKPTvVs6gGTcgYhSb$CsvONG2GJNvvSm1GebykmO414ZlfUuLlDU8+wEu7EcQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tgay",
      "first_name": "Tammy",
      "last_name": "Gay",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:39.119279",
      "role": "patient",
      "email": "tgay@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$84mVtxWhGNQHSf6Jvf7ldj$Pl4k4mvYzGTWYiKFAGilSJ/4rH+PwlGbInceCtPVkI4=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kmiller",
      "first_name": "Kelly",
      "last_name": "Miller",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:39.630921",
      "role": "patient",
      "email": "kmiller@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$pKhIsNdBFi9v3XYOEHfJiL$0X8HYH5f40Bk9av5CAfrR9VmIkaBol/AWzFdwWDywF0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tmcfarland",
      "first_name": "Tanya",
      "last_name": "Mcfarland",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:40.128294",
      "role": "patient",
      "email": "tmcfarland@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$bPKrW12qsxmH21XFNffml5$z5eU/MwZyq33vYzk9W22zWCMnYFldpmBZ0ox4sjqdwc=",
      "last_login": null,
      "is_superuser": 0,
      "username": "pwallace",
      "first_name": "Patrick",
      "last_name": "Wallace",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:40.624356",
      "role": "patient",
      "email": "pwallace@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$EdXDd0csXliw3nCR7Ez014$8+dLZ+J6etLCEXWGc2EHeCULm+UO8Y1pC/sisMMp9PY=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dhall",
      "first_name": "Donald",
      "last_name": "Hall",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:41.052941",
      "role": "patient",
      "email": "dhall@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$H1lYzA1RcsKVXLL0reS6Z6$zNEo/Tyn6azGTkYFukASYMcjUx8oE4Tj6Vh+3Paq79U=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cmelendez",
      "first_name": "Christine",
      "last_name": "Melendez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:41.508258",
      "role": "patient",
      "email": "cmelendez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$cj90sBAfyYxq9Xt6aemKjE$T23gKBkFYksLJU8mOjzTy/7EYRgMOsFzlR+q3Kn10AI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "abanks",
      "first_name": "Allen",
      "last_name": "Banks",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:41.947516",
      "role": "patient",
      "email": "abanks@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$dy0B8rTL5caxxHBPu3tNC2$gHNu10K12qVzEYLReCKlZfBlFQJiudNj3t4zVhaa04w=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jcampbell",
      "first_name": "James",
      "last_name": "Campbell",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:42.402888",
      "role": "patient",
      "email": "jcampbell@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$GURTv9MRjCwwXYALA7xtSu$1vuH1OhCZm9kCnifMQMcLU1cEVZ7kANKwbHhNhvG7Jo=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jknight",
      "first_name": "Justin",
      "last_name": "Knight",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:42.832972",
      "role": "patient",
      "email": "jknight@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$gcSUlsiKvMqDeAo1qE6Vf1$hjbT/meyQbxle9HEU4pGS6KXMPrsdgLoOOEjmdGmgvc=",
      "last_login": null,
      "is_superuser": 0,
      "username": "csavage",
      "first_name": "Cassandra",
      "last_name": "Savage",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:43.275247",
      "role": "patient",
      "email": "csavage@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$oqnHtr9M7NDU4CdKQfrIC1$pvLolXk2fJZab1u733WwVOE/7131yczYV5sI4MK/+Os=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kcortez",
      "first_name": "Kurt",
      "last_name": "Cortez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:43.737505",
      "role": "patient",
      "email": "kcortez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$MramKDmO6XZshWDWjJSusf$UzobuPqCgCbi370zcBpWxHM8DKfS6MIcBEBW3oEFJUE=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rmurillo",
      "first_name": "Richard",
      "last_name": "Murillo",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:44.176888",
      "role": "patient",
      "email": "rmurillo@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$wsShBUXZadg8bprGOe1r7q$T+3oUdzus1XonXoTggdPKEb8o/FSXr3qXbqqjPCH6RY=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mmiller",
      "first_name": "Michelle",
      "last_name": "Miller",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:44.634464",
      "role": "patient",
      "email": "mmiller@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$j7hKknKfyXcuJRtcVktMaM$0v/7NfnkXA7UnkC610QFZPd0qcp0JF0aWd/1nrpBdYA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dallen",
      "first_name": "Dana",
      "last_name": "Allen",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:45.075827",
      "role": "patient",
      "email": "dallen@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$GrsXpxXWCqumj8OOhSMSge$05XgBtS8Q1oCnuFZds//6DTlIdhpWG0GQMU6j7WcQns=",
      "last_login": "2025-07-07 10:51:23.533510",
      "is_superuser": 0,
      "username": "rweeks",
      "first_name": "Renee",
      "last_name": "Weeks",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:45.538810",
      "role": "patient",
      "email": "rweeks@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$vCrBDFIPffltfF016xIikU$HDW0p5xS3h0x/A5WTipeMJUNhuOSFVpAp2Ts+oA34Hs=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mmoore",
      "first_name": "Mark",
      "last_name": "Moore",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:45.990285",
      "role": "patient",
      "email": "mmoore@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$xUsjyfTMc5qpZy7Q1OnNW7$pORkNbFe3k4J1KxsUwC6icTiK8nBLH8C8HROesMx5hc=",
      "last_login": "2026-01-03 11:42:38.748477",
      "is_superuser": 0,
      "username": "tmartinez",
      "first_name": "Teresa",
      "last_name": "Martinez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:46.460254",
      "role": "pharmacist",
      "email": "tmartinez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$yPfKciyssjTwqGjsV85yNM$8cvMds2QbZEkAJgIrPil1VP4IYtdgnFH1r5rV8vREIo=",
      "last_login": null,
      "is_superuser": 0,
      "username": "lcrane",
      "first_name": "Leroy",
      "last_name": "Crane",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:46.921689",
      "role": "pharmacist",
      "email": "lcrane@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$1OxLFXawGYBx7U0sQzGCcU$Sc05Y/lCMnytlU02TFpTcxtt3yukx69e8fcpZSxjHLU=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rleach",
      "first_name": "Rachel",
      "last_name": "Leach",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:47.388156",
      "role": "pharmacist",
      "email": "rleach@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$BYZOAUaYPyk1gFL0jZoW8M$9OQjf797Sx453YaTkjaxJWFPzxJWr93VbyC94MVUB7U=",
      "last_login": null,
      "is_superuser": 0,
      "username": "scarroll",
      "first_name": "Scott",
      "last_name": "Carroll",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:47.840147",
      "role": "patient",
      "email": "scarroll@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ALcnT7KgJ3VNL9H6XSCVat$hmjUoumQJ0yY/9flI5pNXu57qb2R0qkER5cMRa4azOI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cbolton",
      "first_name": "Corey",
      "last_name": "Bolton",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:48.312761",
      "role": "patient",
      "email": "cbolton@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$UscbwAtrflkhPV6mDU3dTW$N5alb0FGAo+8PuodhiqZBQysFK6uXjFZnHCFrmveTWk=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kjimenez",
      "first_name": "Kim",
      "last_name": "Jimenez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:48.772201",
      "role": "patient",
      "email": "kjimenez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$tvxZf29Qr5rEoRyYXaVmOm$8znegHcgPgfHFc5YEN79AW0P/mcRiZvaX0ZE8MmUVO0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "breed",
      "first_name": "Bonnie",
      "last_name": "Reed",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:49.229828",
      "role": "patient",
      "email": "breed@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$kuPLslDH2ICqKI3U2ZxzO7$4huID6wbzz+6NwN97p++KnGKrEr+Oh6+qndVUEKB8mI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tdoyle",
      "first_name": "Timothy",
      "last_name": "Doyle",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:49.738213",
      "role": "patient",
      "email": "tdoyle@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$6JQmHoyujxxCI1rLE2fTWX$Gp0CqfeDXBbESzT5+UWUewFt0VhvHYqJVhDqcNqz08I=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jdecker",
      "first_name": "Jennifer",
      "last_name": "Decker",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:50.219949",
      "role": "patient",
      "email": "jdecker@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$MYmjU9JuDqT2j08dRNRz4i$Up587N805C4tIiZAv2VWZZporsBmpXZ8yX7BH7z/jug=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rbrown",
      "first_name": "Ryan",
      "last_name": "Brown",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:50.736088",
      "role": "patient",
      "email": "rbrown@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$SVCh4X402G56EFi7m5gKcN$zXWI5LbVY/K0VAxhq/QX/3hnZ4e0JBR8DpFHBPvR+ww=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mkelly",
      "first_name": "Michael",
      "last_name": "Kelly",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:51.222311",
      "role": "patient",
      "email": "mkelly@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$bWVAQhqPHLwCtegh6eXkul$KUhXEEi6Jjv06nhxg8ER6iTOcKWg/jvvs3YnZGaHajk=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tstevens",
      "first_name": "Theresa",
      "last_name": "Stevens",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:51.740941",
      "role": "patient",
      "email": "tstevens@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$GKP8QIywDWCYGMnXtepRtp$YHtD1YtwRi/3O//0qUVjrkCVS0HSQTAJmHIBzfHrfX0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mmartin",
      "first_name": "Misty",
      "last_name": "Martin",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:52.225195",
      "role": "patient",
      "email": "mmartin@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$KQemjgztMRmECrE1sYAhN9$P4/FX0rK74bPpc1TAi0mdOP0jtu2gIpQyjxjewy1En8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "janthony",
      "first_name": "Justin",
      "last_name": "Anthony",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:52.721378",
      "role": "patient",
      "email": "janthony@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ZsPNyzqEmyq6MfN1mDLJMX$xcWH/L0kT4xlBH8d13rnIfXu3/7AXFqe7rLMpcEFZH0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "nramos",
      "first_name": "Nicole",
      "last_name": "Ramos",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:53.206083",
      "role": "patient",
      "email": "nramos@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$2SGJKosswjuhex1QXxFHoT$YWxR36wbghJ+8v3JJZYPpM9MiCDjY4czf+D6LOu0kHg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jcombs",
      "first_name": "Jesse",
      "last_name": "Combs",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:53.697199",
      "role": "patient",
      "email": "jcombs@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$fi6bvUZSrV2Rew6kQ3j20v$DICJ5Qs9pTfagosGsqRLA/z3XhE41dDe1A7/L3/wU3U=",
      "last_login": null,
      "is_superuser": 0,
      "username": "trichards",
      "first_name": "Thomas",
      "last_name": "Richards",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:54.170535",
      "role": "patient",
      "email": "trichards@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$5p6Padpk1Ulj2mUjUSjyEP$aqQuCvn/qp4t+AKVbwjT8sm7X//ntn1btlBl2ucWeZw=",
      "last_login": null,
      "is_superuser": 0,
      "username": "vtodd",
      "first_name": "Victor",
      "last_name": "Todd",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:54.661405",
      "role": "patient",
      "email": "vtodd@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$niFFtlN2AeA0r6Udjjmwp2$e8c2dctCDsDuUTVxnZexerZDWe8SFtKF4nxxLdscTHU=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jchapman",
      "first_name": "Justin",
      "last_name": "Chapman",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:55.123263",
      "role": "patient",
      "email": "jchapman@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$8HY9tB06AOGpQ5Q0Ujvys4$FqeR778PexoDfNluxA+0c3IJ9cIxpg8XF3OHnAheyv0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rwilson",
      "first_name": "Robert",
      "last_name": "Wilson",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:55.626502",
      "role": "patient",
      "email": "rwilson@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$E5P9X1kQwPvvE1cdZNvf5j$qLl3KMz9y/MHgrFKIZbqiUiZXaPMmHXvwLB4xGAKnNA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "whubbard",
      "first_name": "William",
      "last_name": "Hubbard",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:56.115813",
      "role": "patient",
      "email": "whubbard@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ytgg6RL0rmlb4aFYJBiOpY$d/Hzfn/+dGBlbja5zPLtLg8M0It+e+hpSblwPrbuAnQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "bhenderson",
      "first_name": "Brandon",
      "last_name": "Henderson",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:56.617717",
      "role": "patient",
      "email": "bhenderson@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ostX0C7GR7mP4HnvsO6J11$bySKVINHy/ziqZZL12GIF9MNIomURCojG4x+5pHQPeE=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tfreeman",
      "first_name": "Terry",
      "last_name": "Freeman",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:57.088173",
      "role": "patient",
      "email": "tfreeman@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$vIUaMW6ZHWxiS2H2ckInnd$SwAk16iu2Y6KX5IirlNTMI2D0vaH0TlFeymkl6gbObQ=",
      "last_login": "2026-01-05 20:37:39.792174",
      "is_superuser": 0,
      "username": "lmason",
      "first_name": "Logan",
      "last_name": "Mason",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:57.605072",
      "role": "pharmacist",
      "email": "lmason@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$Be0frlIdwvxKfaj28pGj20$Jm2G0Aei9Te57O+VlpCR1h7TCgGXzNqMZLiNYAAr4+8=",
      "last_login": "2025-11-06 17:50:45.860365",
      "is_superuser": 0,
      "username": "mfleming",
      "first_name": "Mark",
      "last_name": "Fleming",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:58.083710",
      "role": "pharmacist",
      "email": "mfleming@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$XYiCjzWWCUSZAYbZjpYyxA$0UOSoZDHO7YiLSYfe1XZpiBExJT+KZhMZGQibplbfdA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "godonnell",
      "first_name": "Gregory",
      "last_name": "Odonnell",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:58.598470",
      "role": "pharmacist",
      "email": "godonnell@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$IKx63PrsekI2YGkH0tmbhN$MeKoNoIG8pzrZ15JsBjW6pA2O7VuOC0GL2j4YpxxPuU=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ksims",
      "first_name": "Kathleen",
      "last_name": "Sims",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:59.085900",
      "role": "patient",
      "email": "ksims@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$xfZBEMZOZTG80iiBXDMg0i$V5nqNo1MaK/gDYM3NhIfT3oxHG1MkC6Y02nRRUUVlJA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cjenkins",
      "first_name": "Crystal",
      "last_name": "Jenkins",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:09:59.591005",
      "role": "patient",
      "email": "cjenkins@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$uEVqUalONzyvLzo14dTYmp$O7KCLOYdXFX+712p2CnPIIWRW9eojkuAqcSHIPUc4Ck=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dcolon",
      "first_name": "David",
      "last_name": "Colon",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:00.084021",
      "role": "patient",
      "email": "dcolon@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$Ddv0ZGgyxAFtM1DypfoyDk$4OkP1Pr/Mnl7FM5x8oCQWQ2OW8iKXSXBtP2cqv3QtC4=",
      "last_login": null,
      "is_superuser": 0,
      "username": "msutton",
      "first_name": "Mary",
      "last_name": "Sutton",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:00.598588",
      "role": "patient",
      "email": "msutton@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ZQoOULzx3p71r3H0kkGE2O$gWQFT7BjMpaywYY+LfKCQLp2WuHb/ndwpL7wHqBlbc8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kmullins",
      "first_name": "Karen",
      "last_name": "Mullins",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:01.080133",
      "role": "patient",
      "email": "kmullins@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$mEeQcweeVTi966V61WDGn2$bAFkbA+eMLZsT9eeM/t8NwpcWWMS+w7SNbITiYSDf5s=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ahowell",
      "first_name": "Amy",
      "last_name": "Howell",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:01.589893",
      "role": "patient",
      "email": "ahowell@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$1a0fbmI3ixIfblh4etBuvm$YqtxCSZlwRsGU3HiqG0ovo7y65TWA2VBFYlho6gE1W8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kross",
      "first_name": "Kevin",
      "last_name": "Ross",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:02.084194",
      "role": "patient",
      "email": "kross@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$VGnshCtwTJGH3BQKZqJB1Q$nUgNarVrvaZID41QTIb1OV2IyJFqsch7sWQ9amZKuEQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jcolon",
      "first_name": "Joseph",
      "last_name": "Colon",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:02.822285",
      "role": "patient",
      "email": "jcolon@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$9vzhgpDmCo2sJ0QlVixZsi$1EnFfSXgwVG6/6idrFINCbIG8VYvvgsNiBhn2x3RBMQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "fgreen",
      "first_name": "Frances",
      "last_name": "Green",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:03.458699",
      "role": "patient",
      "email": "fgreen@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$xOvPkrH4nkA1zZpztI50RW$j8LHrbVCGpIDdkMalmxJxibT2x4tak3XvLVnnqb/uyQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jrussell",
      "first_name": "Joseph",
      "last_name": "Russell",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:03.969644",
      "role": "patient",
      "email": "jrussell@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$UGVDOFVEI7MX7oJJhnFtbr$drUk/yHVb+VNy4pXdNAuOuTd7V1XYSpheuHKusnkIM8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "drivas",
      "first_name": "Daryl",
      "last_name": "Rivas",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:04.497322",
      "role": "patient",
      "email": "drivas@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$pBMKOxrIohzCKIMiKMxuT4$M75MPbTOVOYXEjkm7z3Q3cMSjtzC0XV7/o+4YmAWzMI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jmartinez",
      "first_name": "Jose",
      "last_name": "Martinez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:04.988112",
      "role": "patient",
      "email": "jmartinez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$FlrjIknhBJRr6SESPGXszW$N2/lG2TqPgPNSYRMfSUCLiRLWAbZqSgI7QFbxzmvH0w=",
      "last_login": "2025-10-22 10:20:29.618478",
      "is_superuser": 0,
      "username": "jalexander",
      "first_name": "Jamie",
      "last_name": "Alexander",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:05.507099",
      "role": "patient",
      "email": "jalexander@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$MavAWMovBSTNd47A2N8itL$EWzgcNJQNQf4ZLeSLgsCUM5Uqq2DZyhjTJztpGQfnJw=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jmeyers",
      "first_name": "James",
      "last_name": "Meyers",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:06.000944",
      "role": "patient",
      "email": "jmeyers@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$zayqJWumhJa9UDxX3DiwDl$8mXj3xaE0Nn/yIoy8sYlebzNNyjGj/HZruwy2iPTuH0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "adouglas",
      "first_name": "Amanda",
      "last_name": "Douglas",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:06.511342",
      "role": "patient",
      "email": "adouglas@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$CZFEEulotNjYrPZnMEyKwS$ZUB0i0Ylk0Qm5Ix+9HdgDA/5Z8mjNEeMw284SOM5Zv8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tcampos",
      "first_name": "Theresa",
      "last_name": "Campos",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:07.010110",
      "role": "patient",
      "email": "tcampos@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$RMhd1RcUwaAA2q2bP67SPF$jALD7QpHLA2KWjSZ//imWEVb/Nn8yMwrBzEKybX0vGU=",
      "last_login": null,
      "is_superuser": 0,
      "username": "bjones",
      "first_name": "Barbara",
      "last_name": "Jones",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:07.548006",
      "role": "patient",
      "email": "bjones@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$Wp5etZ7g6r4KC965iSsEKt$8u7JPRnpyZGpx37LklmAU8oR3nhn2mRyUXtOyxLyXLE=",
      "last_login": "2025-10-09 11:58:02.519580",
      "is_superuser": 0,
      "username": "ayork",
      "first_name": "Allen",
      "last_name": "York",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:08.068011",
      "role": "patient",
      "email": "ayork@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$dFedUYOu0CNImHtiJHxDF4$yJ6KwHCcGyA+EpkdWRIK0hs6V+PRjBTBI4nlHaBwo3U=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dbates",
      "first_name": "Damon",
      "last_name": "Bates",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:08.581035",
      "role": "patient",
      "email": "dbates@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$nlwPiknz6WLPLJaqA2Ldja$iB8oHica90s3AClpM59AdP1ocDf9d0RkYure4C3Zq+E=",
      "last_login": null,
      "is_superuser": 0,
      "username": "abass",
      "first_name": "Amanda",
      "last_name": "Bass",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:09.076574",
      "role": "patient",
      "email": "abass@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$egIUI8P9uVBCd5RrbsxyqU$QfWf0RiFKu916bR2nYwX3NHW3a9lMbcLLQn48crze6Q=",
      "last_login": null,
      "is_superuser": 0,
      "username": "bcombs",
      "first_name": "Brian",
      "last_name": "Combs",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:09.592117",
      "role": "pharmacist",
      "email": "bcombs@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$2sWoEyAPQFL023rone1hkQ$4nA/j3KgGUHfbxS7zG3sVCwiDjywmKwnr6vb9BmbIxc=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mwelch",
      "first_name": "Mikayla",
      "last_name": "Welch",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:10.102292",
      "role": "pharmacist",
      "email": "mwelch@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$i4kuz985hbnypeTDoiM9dp$65qsG1ihD+hbxzBeqJ8QSdKpWYcs7eAo6HXLMTg2vVg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "wcarlson",
      "first_name": "William",
      "last_name": "Carlson",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:10.626103",
      "role": "pharmacist",
      "email": "wcarlson@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$6f9I4a2bVGoFWGgy8wO3H9$I4/6caw/XVa0/7FM7xzwYIwg82j0IG3xKUHq0y2qbW0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mweber",
      "first_name": "Michael",
      "last_name": "Weber",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:11.128463",
      "role": "patient",
      "email": "mweber@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$O3ck9CbJhfs6mFuLGtLc2U$ypV9Kea7v8u7pVis5qRg7WO0vaOIIyrEATNyq/ah05c=",
      "last_login": null,
      "is_superuser": 0,
      "username": "amartinez",
      "first_name": "Angela",
      "last_name": "Martinez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:11.766472",
      "role": "patient",
      "email": "amartinez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$WkmCK0On32KhRRaD8WnfEd$fhv0GifZKJtC/8Q9cCy7wlPiTScMWAcpxsy+Pt1o5kY=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dperry",
      "first_name": "Douglas",
      "last_name": "Perry",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:12.363981",
      "role": "patient",
      "email": "dperry@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$0guvF3I3FiEEt4lZY5ECc7$mZocw9bDmxaBlkvOrT+M849SqZa8WXP9Kr42Choyfno=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jhunt",
      "first_name": "James",
      "last_name": "Hunt",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:12.854337",
      "role": "patient",
      "email": "jhunt@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$sen8scwPFDKGNw1Y3NzQof$iis0yVeC66us4V3Ab1UQlpAl1QvX9gT0AxBLjGKcWqA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jcameron",
      "first_name": "Jonathan",
      "last_name": "Cameron",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:13.382129",
      "role": "patient",
      "email": "jcameron@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$8aFIuruWc79VhyQWcJOFg4$O09oKam/5IICs1KeYY4t848r9zrk/BHcpFaGQIerS2E=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cstewart",
      "first_name": "Carl",
      "last_name": "Stewart",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:13.886931",
      "role": "patient",
      "email": "cstewart@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$aWQDjYlKbJJP3hExtIAIpc$QFQkmY3pRvpqgGk6IzUEmlKMe6KEZQJ7w8HHTcuxVC8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jdonovan",
      "first_name": "Jerry",
      "last_name": "Donovan",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:14.405643",
      "role": "patient",
      "email": "jdonovan@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$errrRIBAGXlmbH5uzu7I40$5nBtZoGU1q9GwNyN30I9T8YKtqHzw9LEWL+xJBhugok=",
      "last_login": null,
      "is_superuser": 0,
      "username": "shamilton",
      "first_name": "Sara",
      "last_name": "Hamilton",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:14.909702",
      "role": "patient",
      "email": "shamilton@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$u3PN6Fl7rq0nxdcbgbbc7R$VN+jZlonuq9OSbVTravb96nWGzsQ+C+aDFy3cL2NGso=",
      "last_login": null,
      "is_superuser": 0,
      "username": "atrujillo",
      "first_name": "Adrienne",
      "last_name": "Trujillo",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:15.457101",
      "role": "patient",
      "email": "atrujillo@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$v60XW8ffnO5tPvGS139of7$AAktYdrB+XuchhjxqqKeRzh9i+A5hk3gljHpzlu1q0M=",
      "last_login": null,
      "is_superuser": 0,
      "username": "creed",
      "first_name": "Crystal",
      "last_name": "Reed",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:15.952997",
      "role": "patient",
      "email": "creed@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$xgw3VjUqjHWiwsKKEaDJYi$8b8rqKQThhZ4jeGtatkpQmwEU1qiEnQxGfF7zGZox0A=",
      "last_login": null,
      "is_superuser": 0,
      "username": "wturner",
      "first_name": "Wayne",
      "last_name": "Turner",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:16.476410",
      "role": "patient",
      "email": "wturner@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ZmiNDX7KcPFRx6SwGPSEQQ$dxJ4/WZDfP9SenyoVTmEIgaecigJdAiQoNoS7YtpiLE=",
      "last_login": null,
      "is_superuser": 0,
      "username": "wphillips",
      "first_name": "William",
      "last_name": "Phillips",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:16.996365",
      "role": "patient",
      "email": "wphillips@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$MlxRUjGSUR04wiHZwe7pIH$G2MCVzAqD6H0UX9G0c8zZWaF5prZIoC8ImablV5XXUU=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jmcguire",
      "first_name": "Jason",
      "last_name": "Mcguire",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:17.535494",
      "role": "patient",
      "email": "jmcguire@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$GB3trX5BE3VhB2KokjC2xg$q0nWj03LMV3OzqrzLCqRZR68eELpEe5KN7KgdqbTExQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ttorres",
      "first_name": "Tina",
      "last_name": "Torres",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:18.050709",
      "role": "patient",
      "email": "ttorres@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$w1rc89OQN8pcsp7LthOVQ2$XQI/b+jZcY08wiovcjUktW7L0fQnNUej1uHmifEynx0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "lcook",
      "first_name": "Lawrence",
      "last_name": "Cook",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:18.575119",
      "role": "patient",
      "email": "lcook@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$uMIVPeU9R2Pkk4v3Y0F298$WpjjbRV97a2oPkzen2WyvP2yWItMBmSfoN6dQKHzkdQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "rdiaz",
      "first_name": "Robin",
      "last_name": "Diaz",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:19.093350",
      "role": "patient",
      "email": "rdiaz@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$C5wB7e93pQCyd9feZ1uwon$iXphibktZnHpO2raydETQmJq444ZDmgqHnpreQl3qyg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "lmendoza",
      "first_name": "Luis",
      "last_name": "Mendoza",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:19.629365",
      "role": "patient",
      "email": "lmendoza@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$xi8WphdTXHBl1YI4XJQKys$yuXqldmB0wUuT/N/+qaFFGAM864DrAtiOSbU+26nzMA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cphillips",
      "first_name": "Charles",
      "last_name": "Phillips",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:20.139601",
      "role": "patient",
      "email": "cphillips@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$PUN7ZEL5m8t0WNRpKWuZOU$4gWNbRZ/0hERvgVPcY7GVCHuJiFPOLKgAqa2i1KkB9Q=",
      "last_login": null,
      "is_superuser": 0,
      "username": "crodriguez",
      "first_name": "Charles",
      "last_name": "Rodriguez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:20.676702",
      "role": "patient",
      "email": "crodriguez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$fi8GteOPimW8BlFOTbvnyl$wRIH/b+s5+MEMQ9vAY8b1A1nIpL2t6KGWOY0lyuVrEM=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tmorgan",
      "first_name": "Tanya",
      "last_name": "Morgan",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:21.189783",
      "role": "patient",
      "email": "tmorgan@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$3cN0Fk3FVLDt6eM3cVrRC7$Y3CCCSMZ53np2+4ZUtrr+azIRqALGRI5rF/DcxVKwUA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "cwarner",
      "first_name": "Christopher",
      "last_name": "Warner",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:21.738072",
      "role": "pharmacist",
      "email": "cwarner@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$WGlNTwXS3ld8sS0Ekh9i4B$Y6Y+cGciEB5eCJyu1WxuH3z//MJVfDJlVxzLReFT+5g=",
      "last_login": null,
      "is_superuser": 0,
      "username": "vwilliams",
      "first_name": "Vincent",
      "last_name": "Williams",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:22.252884",
      "role": "pharmacist",
      "email": "vwilliams@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$9reMiRK4Eu00vAajPgdPTR$PlRogrZY/aSU0QSebJfFFDv9wvzMxsQzgoMSUgCmeSg=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ljohnson",
      "first_name": "Leslie",
      "last_name": "Johnson",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:22.795304",
      "role": "pharmacist",
      "email": "ljohnson@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ySicjv8wiYVjq0gXNuCH2X$GBxdKa9IwY0rCDa9hFUVKYT+pzENHhoOgJ8qBssXtNA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mdavis",
      "first_name": "Megan",
      "last_name": "Davis",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:23.318049",
      "role": "patient",
      "email": "mdavis@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$F7Ye1Fw2zlwJoWK4hIiIiG$Qce195pR+ZIF5Med/HWxs3AsyBISRH0WgkUtNl1uzU8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "lnichols",
      "first_name": "Lauren",
      "last_name": "Nichols",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:23.831441",
      "role": "patient",
      "email": "lnichols@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$aXhcDa9bbHPCVwDps9KEbT$+mmCim/lMz9iSQIUIAOHETMVUTeIH/LNuDVYoCo//JI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "mberry",
      "first_name": "Miranda",
      "last_name": "Berry",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:24.357898",
      "role": "patient",
      "email": "mberry@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$TpIhpJn0lnTCrnruO99MAS$tvywuCr3Fq1rIWYBpv0AyEaUWhWRcw2Zyz9NV9zr28k=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kmccoy",
      "first_name": "Kelsey",
      "last_name": "Mccoy",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:24.867054",
      "role": "patient",
      "email": "kmccoy@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$dQgcBQGg8o1E9a4nMsq6ju$a+adMLurkB55QqSAI3L4MP4oeQTKY/ZraMiWVItTg7c=",
      "last_login": null,
      "is_superuser": 0,
      "username": "bvasquez",
      "first_name": "Brittany",
      "last_name": "Vasquez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:25.411020",
      "role": "patient",
      "email": "bvasquez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$1iTB4K7B0fq9gP5r4ZxkRw$eM5bt570EgSndHsrJYe3ergYxtEjUC0CLH1sZNI1474=",
      "last_login": null,
      "is_superuser": 0,
      "username": "sclayton",
      "first_name": "Sarah",
      "last_name": "Clayton",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:25.920132",
      "role": "patient",
      "email": "sclayton@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$ZtiYzDmC32MOUVMrZJZOyF$ZBSQAva4vTWPwQqOtB6NdCmWYRfxAnacuE60VFSyGt4=",
      "last_login": null,
      "is_superuser": 0,
      "username": "dzamora",
      "first_name": "Dave",
      "last_name": "Zamora",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:26.473921",
      "role": "patient",
      "email": "dzamora@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$7XKF9xD4m6dnHHa3fjWnEO$XO5fYpECJSfZlDTZwDCtnmF10/KUnGgXV8Dk/dmtttQ=",
      "last_login": null,
      "is_superuser": 0,
      "username": "award",
      "first_name": "Angel",
      "last_name": "Ward",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:26.980284",
      "role": "patient",
      "email": "award@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$5bxBELznua8eELvfbpEwfQ$edVOPQeD0GJkJmff9pUvTRoGUnUCdR76f5YeQ0yV2c0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jlowe",
      "first_name": "Joe",
      "last_name": "Lowe",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:27.522637",
      "role": "patient",
      "email": "jlowe@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$wmvyiYDdkn9vdmHSipjdjw$/2LG+F2+yyX9sFpHP6MuWwxeV7S1u7kFrzQMWSSu2PA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "afoster",
      "first_name": "Allison",
      "last_name": "Foster",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:28.032003",
      "role": "patient",
      "email": "afoster@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$44Pz7AyzHxgOvzEdFHJcpS$wCJb6KW6xjzOFpWGJD9G13XuoTrhQtu707wvH0N16qM=",
      "last_login": null,
      "is_superuser": 0,
      "username": "bkennedy",
      "first_name": "Brian",
      "last_name": "Kennedy",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:28.590001",
      "role": "patient",
      "email": "bkennedy@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$zrWd3lLLEgscgqwaxcoPgW$4gqGvPcQMb5YTZIqZBO5J13WaHgMVC3XY0YliNNrGeA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "wcruz",
      "first_name": "Wanda",
      "last_name": "Cruz",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:29.110926",
      "role": "patient",
      "email": "wcruz@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$bqgSTkujJgwXHuKnjIzda7$N33vv7fivQ8ysesaNGE71DMlsRkLMZc5260aAVAgEbo=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kshelton",
      "first_name": "Kevin",
      "last_name": "Shelton",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:29.646319",
      "role": "patient",
      "email": "kshelton@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$IVdoPZGvI9fF3Hatgekd35$AWdVc4qVB6K1se+X4B9JYa5yPw4N3CJrin7tNPv8Ars=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jhernandez",
      "first_name": "Joshua",
      "last_name": "Hernandez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:30.169192",
      "role": "patient",
      "email": "jhernandez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$cZNxXsnA9KcXnSsQKiBZ04$XdIu95tQnvqQnacQdCbn2tFEumpXKWqGfymVkJwi/PI=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ajordan",
      "first_name": "Ashley",
      "last_name": "Jordan",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:30.710111",
      "role": "patient",
      "email": "ajordan@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$uXK7tbLL9lNL11RPuzd93C$x5dYickvUZZPmXsVeN6OfuEU62N+y88xdnUF0iabup8=",
      "last_login": null,
      "is_superuser": 0,
      "username": "agallagher",
      "first_name": "Ashley",
      "last_name": "Gallagher",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:31.238535",
      "role": "patient",
      "email": "agallagher@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$voQr7ceZ2FRni5Br8odnqZ$yGO3ovHj4qy/CZ+zS5w4sW5bDvrllVjSO6NHv/HDiL0=",
      "last_login": null,
      "is_superuser": 0,
      "username": "jvincent",
      "first_name": "Jesse",
      "last_name": "Vincent",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:31.848950",
      "role": "patient",
      "email": "jvincent@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$yT2X4W7U2kvxe9PMkKJ5FM$5qe6rnSkG0wTA2bMT9TA2FtA73uel4dOh0+n46NffL4=",
      "last_login": null,
      "is_superuser": 0,
      "username": "ktate",
      "first_name": "Kelly",
      "last_name": "Tate",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:32.394564",
      "role": "patient",
      "email": "ktate@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$gLTbWsPDdiD6OIkjsoJ80K$wNi40dnLRQOCIBecGCagLushG3Z6P8tyDSiK6ShvYEo=",
      "last_login": "2025-09-19 11:21:02.264068",
      "is_superuser": 0,
      "username": "bgomez",
      "first_name": "Brian",
      "last_name": "Gomez",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:32.917019",
      "role": "patient",
      "email": "bgomez@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$720000$4Bj6xlTUwO713aALD1yJfv$cObq4mIezwRbp/b9dxTA7vWjjlN9SRRZAyh8FHARoXs=",
      "last_login": null,
      "is_superuser": 0,
      "username": "kturner",
      "first_name": "Kyle",
      "last_name": "Turner",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-06-12 11:10:33.453207",
      "role": "patient",
      "email": "kturner@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "system123",
      "last_login": "2025-10-02 12:14:11",
      "is_superuser": 1,
      "username": "system",
      "first_name": "Notification",
      "last_name": "System",
      "is_staff": 1,
      "is_active": 1,
      "date_joined": "2025-10-02 12:08:06",
      "role": "system",
      "email": "noreply@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$DTqkkFsAzXIFvEYH4UZ08u$2pTHUPfyDp1rA9Ufn0WenDXwYpecKPylzX1nhpKoXGw=",
      "last_login": "2025-12-01 22:43:06.877050",
      "is_superuser": 0,
      "username": "kgeorge",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 22:30:25.871554",
      "role": "patient",
      "email": "kgeorge@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$T7rMN1Vh35OoP1pSpdWPca$1QvoVVvj2y8btEmsDYEhWSO20sKwNYugWvRQQ2lRPSA=",
      "last_login": null,
      "is_superuser": 0,
      "username": "tshelby",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 22:35:47.409395",
      "role": "pharmacist",
      "email": "tshelby@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$AYqVJ7UaBlvn9vQ7g7XCLZ$inIyZkKUzyIMOIpn8hzAGXsxjU3wTYfrPQYP5tIC91U=",
      "last_login": "2025-12-01 22:36:42.686402",
      "is_superuser": 0,
      "username": "tshelby21",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 22:36:42.172814",
      "role": "pharmacist",
      "email": "tshelby21@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$kyvKiwWfJvH4TcpamzykSP$ilLvkCHnxtMeD/BfJEODB9f4ht5HG0n9KhXxnZFf81Y=",
      "last_login": "2025-12-01 23:22:15.562696",
      "is_superuser": 0,
      "username": "sgeorge27",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 22:39:34.196950",
      "role": "pharmacy admin",
      "email": "sgeorge27@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$ywZdJmgqDvGD8ivKNkz1sI$DkTzlmhoG0/oi/mnZpOjIjvRK06YvAab7uCj8Gjww5o=",
      "last_login": "2025-12-01 23:23:48.463865",
      "is_superuser": 0,
      "username": "jmcain",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 23:23:00.474296",
      "role": "pharmacist",
      "email": "jmcain@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$Pj9kKuKIDvwLDcT8CP7ugz$NLdB5/z181+LmZ8X3SqnqwiqBel7PRqdNDbGABANouk=",
      "last_login": "2025-12-01 23:23:35.307715",
      "is_superuser": 0,
      "username": "jmcain12",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-01 23:23:34.794544",
      "role": "pharmacist",
      "email": "jmcain12@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$gBcYwJLPpo4v5uuXSjrLZX$5PNKuA9Yeh0T4JVoRTfNwfDYA6+uhs5V4AZqJy51hOk=",
      "last_login": "2025-12-10 19:21:44.031746",
      "is_superuser": 0,
      "username": "Josh",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-10 19:21:43.321654",
      "role": "patient",
      "email": "Josh@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$sKtb1JrMu5MSfe5pGKTNrJ$Lvmkyj3KMmqb1yK9MnvBi/3VM1Cc17QmN+F7X1cwr6M=",
      "last_login": "2025-12-10 19:26:41.173992",
      "is_superuser": 0,
      "username": "Craig",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-10 19:26:40.520742",
      "role": "patient",
      "email": "Craig@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$X2jUTKMd6T7gs0dFOJGURQ$S6yUVFMRSCl2rTFmX1PCBxJvYV3dnnVEG+B9NNa5SRw=",
      "last_login": "2025-12-10 19:30:12.772043",
      "is_superuser": 0,
      "username": "Johnny",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-10 19:30:12.138077",
      "role": "patient",
      "email": "Johnny@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$7Z0k66fg2nw8viB0O2ZseT$Sz2DC9PTvUXufw6IUrVCYko2mWeoKIYuBDGVDcOBXkA=",
      "last_login": "2025-12-31 22:40:26.368218",
      "is_superuser": 0,
      "username": "woodlands_phar",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-31 22:40:25.825357",
      "role": "pharmacy admin",
      "email": "woodlandspharm@mail.com"
    }
  },
  {
    "model": "accounts.customaccount",
    "fields": {
      "password": "pbkdf2_sha256$600000$imPxx8DHI4cPmlIuXGvY9w$VWK+yd7lTjT6vS+1Y6GT3AjoAsxok6XkjtlOt80woYQ=",
      "last_login": "2026-01-03 12:38:51.951743",
      "is_superuser": 0,
      "username": "ngeorge1",
      "first_name": "",
      "last_name": "",
      "is_staff": 0,
      "is_active": 1,
      "date_joined": "2025-12-31 22:57:14.284086",
      "role": "patient",
      "email": "ngeorge12@mail.com"
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1995-04-23",
      "gender": "M",
      "user_id": 17,
      "first_name": "Justin",
      "last_name": "Jackson",
      "phone_number": "215-987-4567",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1944-03-18",
      "gender": "F",
      "user_id": 305,
      "first_name": "Andrea",
      "last_name": "Camacho",
      "phone_number": "574-560-2117",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1958-05-21",
      "gender": "F",
      "user_id": 306,
      "first_name": "Jordan",
      "last_name": "Price",
      "phone_number": "333-590-6745",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1992-12-28",
      "gender": "F",
      "user_id": 307,
      "first_name": "Jodi",
      "last_name": "Moore",
      "phone_number": "753-552-1322",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1953-11-02",
      "gender": "M",
      "user_id": 308,
      "first_name": "Mark",
      "last_name": "Perez",
      "phone_number": "974-777-0916",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1951-10-27",
      "gender": "F",
      "user_id": 309,
      "first_name": "Tammy",
      "last_name": "Gay",
      "phone_number": "479-137-3333",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1936-11-21",
      "gender": "F",
      "user_id": 310,
      "first_name": "Kelly",
      "last_name": "Miller",
      "phone_number": "297-351-0056",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1981-09-21",
      "gender": "F",
      "user_id": 311,
      "first_name": "Tanya",
      "last_name": "Mcfarland",
      "phone_number": "768-630-0008",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1972-06-03",
      "gender": "M",
      "user_id": 312,
      "first_name": "Patrick",
      "last_name": "Wallace",
      "phone_number": "572-520-3503",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1938-08-20",
      "gender": "M",
      "user_id": 313,
      "first_name": "Donald",
      "last_name": "Hall",
      "phone_number": "813-376-6549",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1982-06-27",
      "gender": "F",
      "user_id": 314,
      "first_name": "Christine",
      "last_name": "Melendez",
      "phone_number": "085-061-6387",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1959-04-26",
      "gender": "M",
      "user_id": 315,
      "first_name": "Allen",
      "last_name": "Banks",
      "phone_number": "437-674-5826",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1981-11-24",
      "gender": "M",
      "user_id": 316,
      "first_name": "James",
      "last_name": "Campbell",
      "phone_number": "879-274-2176",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1960-05-03",
      "gender": "M",
      "user_id": 317,
      "first_name": "Justin",
      "last_name": "Knight",
      "phone_number": "823-923-1182",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-04-16",
      "gender": "F",
      "user_id": 318,
      "first_name": "Cassandra",
      "last_name": "Savage",
      "phone_number": "238-514-1666",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1977-10-15",
      "gender": "M",
      "user_id": 319,
      "first_name": "Kurt",
      "last_name": "Cortez",
      "phone_number": "461-204-4662",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1969-04-12",
      "gender": "M",
      "user_id": 320,
      "first_name": "Richard",
      "last_name": "Murillo",
      "phone_number": "822-837-3783",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1982-11-19",
      "gender": "F",
      "user_id": 321,
      "first_name": "Michelle",
      "last_name": "Miller",
      "phone_number": "096-926-8993",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1969-05-07",
      "gender": "F",
      "user_id": 322,
      "first_name": "Dana",
      "last_name": "Allen",
      "phone_number": "986-887-6201",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2006-06-25",
      "gender": "F",
      "user_id": 323,
      "first_name": "Renee",
      "last_name": "Weeks",
      "phone_number": "615-290-6174",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1974-11-27",
      "gender": "M",
      "user_id": 324,
      "first_name": "Mark",
      "last_name": "Moore",
      "phone_number": "564-076-8890",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1953-06-19",
      "gender": "M",
      "user_id": 328,
      "first_name": "Scott",
      "last_name": "Carroll",
      "phone_number": "301-171-4281",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1973-03-02",
      "gender": "M",
      "user_id": 329,
      "first_name": "Corey",
      "last_name": "Bolton",
      "phone_number": "588-032-3052",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1945-06-11",
      "gender": "F",
      "user_id": 330,
      "first_name": "Kim",
      "last_name": "Jimenez",
      "phone_number": "976-665-5149",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1988-07-22",
      "gender": "F",
      "user_id": 331,
      "first_name": "Bonnie",
      "last_name": "Reed",
      "phone_number": "641-820-7904",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1973-02-10",
      "gender": "M",
      "user_id": 332,
      "first_name": "Timothy",
      "last_name": "Doyle",
      "phone_number": "361-321-9011",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1971-12-21",
      "gender": "F",
      "user_id": 333,
      "first_name": "Jennifer",
      "last_name": "Decker",
      "phone_number": "686-068-1993",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1967-08-13",
      "gender": "M",
      "user_id": 334,
      "first_name": "Ryan",
      "last_name": "Brown",
      "phone_number": "571-029-4984",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1959-07-22",
      "gender": "M",
      "user_id": 335,
      "first_name": "Michael",
      "last_name": "Kelly",
      "phone_number": "048-234-1359",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1960-02-10",
      "gender": "F",
      "user_id": 336,
      "first_name": "Theresa",
      "last_name": "Stevens",
      "phone_number": "839-393-2057",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1987-10-04",
      "gender": "F",
      "user_id": 337,
      "first_name": "Misty",
      "last_name": "Martin",
      "phone_number": "807-627-0988",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1993-02-28",
      "gender": "M",
      "user_id": 338,
      "first_name": "Justin",
      "last_name": "Anthony",
      "phone_number": "679-166-7338",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1984-03-19",
      "gender": "F",
      "user_id": 339,
      "first_name": "Nicole",
      "last_name": "Ramos",
      "phone_number": "949-770-1276",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1989-12-03",
      "gender": "M",
      "user_id": 340,
      "first_name": "Jesse",
      "last_name": "Combs",
      "phone_number": "240-258-0995",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1976-03-09",
      "gender": "M",
      "user_id": 341,
      "first_name": "Thomas",
      "last_name": "Richards",
      "phone_number": "734-626-2395",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1976-04-03",
      "gender": "M",
      "user_id": 342,
      "first_name": "Victor",
      "last_name": "Todd",
      "phone_number": "665-672-7609",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1970-01-07",
      "gender": "M",
      "user_id": 343,
      "first_name": "Justin",
      "last_name": "Chapman",
      "phone_number": "658-463-4306",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1985-12-25",
      "gender": "M",
      "user_id": 344,
      "first_name": "Robert",
      "last_name": "Wilson",
      "phone_number": "802-804-1043",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1976-12-18",
      "gender": "M",
      "user_id": 345,
      "first_name": "William",
      "last_name": "Hubbard",
      "phone_number": "627-350-1472",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1982-02-13",
      "gender": "M",
      "user_id": 346,
      "first_name": "Brandon",
      "last_name": "Henderson",
      "phone_number": "068-746-9574",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1987-10-08",
      "gender": "M",
      "user_id": 347,
      "first_name": "Terry",
      "last_name": "Freeman",
      "phone_number": "782-053-9816",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2000-05-20",
      "gender": "F",
      "user_id": 351,
      "first_name": "Kathleen",
      "last_name": "Sims",
      "phone_number": "901-141-7681",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1988-01-07",
      "gender": "F",
      "user_id": 352,
      "first_name": "Crystal",
      "last_name": "Jenkins",
      "phone_number": "708-313-2005",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1989-12-28",
      "gender": "M",
      "user_id": 353,
      "first_name": "David",
      "last_name": "Colon",
      "phone_number": "458-353-4011",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2007-05-08",
      "gender": "F",
      "user_id": 354,
      "first_name": "Mary",
      "last_name": "Sutton",
      "phone_number": "563-706-9724",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1942-08-27",
      "gender": "F",
      "user_id": 355,
      "first_name": "Karen",
      "last_name": "Mullins",
      "phone_number": "311-832-9309",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1951-07-01",
      "gender": "F",
      "user_id": 356,
      "first_name": "Amy",
      "last_name": "Howell",
      "phone_number": "439-439-3664",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1937-05-13",
      "gender": "M",
      "user_id": 357,
      "first_name": "Kevin",
      "last_name": "Ross",
      "phone_number": "286-470-7706",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1975-01-26",
      "gender": "M",
      "user_id": 358,
      "first_name": "Joseph",
      "last_name": "Colon",
      "phone_number": "026-210-6305",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1994-05-28",
      "gender": "F",
      "user_id": 359,
      "first_name": "Frances",
      "last_name": "Green",
      "phone_number": "349-359-5433",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1965-07-25",
      "gender": "M",
      "user_id": 360,
      "first_name": "Joseph",
      "last_name": "Russell",
      "phone_number": "177-152-0323",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2001-06-18",
      "gender": "M",
      "user_id": 361,
      "first_name": "Daryl",
      "last_name": "Rivas",
      "phone_number": "446-527-5711",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1979-03-10",
      "gender": "M",
      "user_id": 362,
      "first_name": "Jose",
      "last_name": "Martinez",
      "phone_number": "968-094-4163",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1950-03-15",
      "gender": "F",
      "user_id": 363,
      "first_name": "Jamie",
      "last_name": "Alexander",
      "phone_number": "885-592-1018",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-06-20",
      "gender": "M",
      "user_id": 364,
      "first_name": "James",
      "last_name": "Meyers",
      "phone_number": "029-468-3333",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1942-10-22",
      "gender": "F",
      "user_id": 365,
      "first_name": "Amanda",
      "last_name": "Douglas",
      "phone_number": "157-643-5064",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2006-09-11",
      "gender": "F",
      "user_id": 366,
      "first_name": "Theresa",
      "last_name": "Campos",
      "phone_number": "190-926-6737",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1945-08-20",
      "gender": "F",
      "user_id": 367,
      "first_name": "Barbara",
      "last_name": "Jones",
      "phone_number": "475-675-2250",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1974-06-05",
      "gender": "M",
      "user_id": 368,
      "first_name": "Allen",
      "last_name": "York",
      "phone_number": "037-159-3739",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1983-09-23",
      "gender": "M",
      "user_id": 369,
      "first_name": "Damon",
      "last_name": "Bates",
      "phone_number": "708-423-0643",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1937-06-09",
      "gender": "F",
      "user_id": 370,
      "first_name": "Amanda",
      "last_name": "Bass",
      "phone_number": "397-279-8527",
      "pharmacy_id": 3
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1964-01-10",
      "gender": "M",
      "user_id": 374,
      "first_name": "Michael",
      "last_name": "Weber",
      "phone_number": "386-103-3523",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1987-03-16",
      "gender": "F",
      "user_id": 375,
      "first_name": "Angela",
      "last_name": "Martinez",
      "phone_number": "687-884-7742",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1985-02-07",
      "gender": "M",
      "user_id": 376,
      "first_name": "Douglas",
      "last_name": "Perry",
      "phone_number": "523-082-6664",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1972-03-14",
      "gender": "M",
      "user_id": 377,
      "first_name": "James",
      "last_name": "Hunt",
      "phone_number": "273-600-1468",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1980-12-16",
      "gender": "M",
      "user_id": 378,
      "first_name": "Jonathan",
      "last_name": "Cameron",
      "phone_number": "402-327-5689",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1945-03-20",
      "gender": "M",
      "user_id": 379,
      "first_name": "Carl",
      "last_name": "Stewart",
      "phone_number": "353-972-8445",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1987-12-08",
      "gender": "M",
      "user_id": 380,
      "first_name": "Jerry",
      "last_name": "Donovan",
      "phone_number": "815-947-1009",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2004-11-28",
      "gender": "F",
      "user_id": 381,
      "first_name": "Sara",
      "last_name": "Hamilton",
      "phone_number": "099-026-3941",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1954-08-12",
      "gender": "F",
      "user_id": 382,
      "first_name": "Adrienne",
      "last_name": "Trujillo",
      "phone_number": "046-627-2169",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1938-06-24",
      "gender": "F",
      "user_id": 383,
      "first_name": "Crystal",
      "last_name": "Reed",
      "phone_number": "674-237-9741",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-04-21",
      "gender": "M",
      "user_id": 384,
      "first_name": "Wayne",
      "last_name": "Turner",
      "phone_number": "937-480-5512",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2005-11-14",
      "gender": "M",
      "user_id": 385,
      "first_name": "William",
      "last_name": "Phillips",
      "phone_number": "803-667-0923",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1983-05-18",
      "gender": "M",
      "user_id": 386,
      "first_name": "Jason",
      "last_name": "Mcguire",
      "phone_number": "346-054-3358",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1947-01-31",
      "gender": "F",
      "user_id": 387,
      "first_name": "Tina",
      "last_name": "Torres",
      "phone_number": "560-090-0378",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1961-02-28",
      "gender": "M",
      "user_id": 388,
      "first_name": "Lawrence",
      "last_name": "Cook",
      "phone_number": "331-132-9837",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1988-11-18",
      "gender": "F",
      "user_id": 389,
      "first_name": "Robin",
      "last_name": "Diaz",
      "phone_number": "596-450-4333",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1939-10-11",
      "gender": "M",
      "user_id": 390,
      "first_name": "Luis",
      "last_name": "Mendoza",
      "phone_number": "990-896-0894",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2005-02-27",
      "gender": "M",
      "user_id": 391,
      "first_name": "Charles",
      "last_name": "Phillips",
      "phone_number": "607-315-2647",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2007-06-01",
      "gender": "M",
      "user_id": 392,
      "first_name": "Charles",
      "last_name": "Rodriguez",
      "phone_number": "784-686-8172",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-01-04",
      "gender": "F",
      "user_id": 393,
      "first_name": "Tanya",
      "last_name": "Morgan",
      "phone_number": "208-036-6735",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2004-08-08",
      "gender": "F",
      "user_id": 397,
      "first_name": "Megan",
      "last_name": "Davis",
      "phone_number": "622-257-9776",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1946-10-22",
      "gender": "F",
      "user_id": 398,
      "first_name": "Lauren",
      "last_name": "Nichols",
      "phone_number": "218-973-3060",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1978-12-10",
      "gender": "F",
      "user_id": 399,
      "first_name": "Miranda",
      "last_name": "Berry",
      "phone_number": "856-695-8952",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1970-01-03",
      "gender": "F",
      "user_id": 400,
      "first_name": "Kelsey",
      "last_name": "Mccoy",
      "phone_number": "495-194-0886",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1963-04-22",
      "gender": "F",
      "user_id": 401,
      "first_name": "Brittany",
      "last_name": "Vasquez",
      "phone_number": "083-877-4324",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1966-11-30",
      "gender": "F",
      "user_id": 402,
      "first_name": "Sarah",
      "last_name": "Clayton",
      "phone_number": "124-067-4167",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1975-08-09",
      "gender": "M",
      "user_id": 403,
      "first_name": "Dave",
      "last_name": "Zamora",
      "phone_number": "554-154-8742",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1965-06-04",
      "gender": "F",
      "user_id": 404,
      "first_name": "Angel",
      "last_name": "Ward",
      "phone_number": "833-869-5938",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1971-07-06",
      "gender": "M",
      "user_id": 405,
      "first_name": "Joe",
      "last_name": "Lowe",
      "phone_number": "824-235-6386",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1975-08-07",
      "gender": "F",
      "user_id": 406,
      "first_name": "Allison",
      "last_name": "Foster",
      "phone_number": "331-129-9489",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1963-10-16",
      "gender": "M",
      "user_id": 407,
      "first_name": "Brian",
      "last_name": "Kennedy",
      "phone_number": "260-910-5031",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1974-08-23",
      "gender": "F",
      "user_id": 408,
      "first_name": "Wanda",
      "last_name": "Cruz",
      "phone_number": "697-281-1374",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1996-05-21",
      "gender": "M",
      "user_id": 409,
      "first_name": "Kevin",
      "last_name": "Shelton",
      "phone_number": "250-586-6401",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-01-29",
      "gender": "M",
      "user_id": 410,
      "first_name": "Joshua",
      "last_name": "Hernandez",
      "phone_number": "068-487-4246",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2003-05-02",
      "gender": "F",
      "user_id": 411,
      "first_name": "Ashley",
      "last_name": "Jordan",
      "phone_number": "825-881-3026",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1998-12-20",
      "gender": "F",
      "user_id": 412,
      "first_name": "Ashley",
      "last_name": "Gallagher",
      "phone_number": "437-790-3213",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1986-01-02",
      "gender": "M",
      "user_id": 413,
      "first_name": "Jesse",
      "last_name": "Vincent",
      "phone_number": "667-176-8073",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1983-01-02",
      "gender": "F",
      "user_id": 414,
      "first_name": "Kelly",
      "last_name": "Tate",
      "phone_number": "514-489-3775",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1935-12-10",
      "gender": "M",
      "user_id": 415,
      "first_name": "Brian",
      "last_name": "Gomez",
      "phone_number": "274-354-3514",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1953-03-18",
      "gender": "M",
      "user_id": 416,
      "first_name": "Kyle",
      "last_name": "Turner",
      "phone_number": "093-995-8519",
      "pharmacy_id": 5
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1988-03-21",
      "gender": "M",
      "user_id": 418,
      "first_name": "Keith",
      "last_name": "George",
      "phone_number": "267-255-1088",
      "pharmacy_id": 2
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1999-12-17",
      "gender": "M",
      "user_id": 424,
      "first_name": "Josh",
      "last_name": "George",
      "phone_number": "2674744395",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1999-12-10",
      "gender": "M",
      "user_id": 425,
      "first_name": "Craig",
      "last_name": "David",
      "phone_number": "2674744395",
      "pharmacy_id": 1
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "1998-12-09",
      "gender": "M",
      "user_id": 426,
      "first_name": "Johnny",
      "last_name": "Sack",
      "phone_number": "2674744395",
      "pharmacy_id": 4
    }
  },
  {
    "model": "patients.patientprofile",
    "fields": {
      "dob": "2006-04-09",
      "gender": "O",
      "user_id": 428,
      "first_name": "Nick",
      "last_name": "George",
      "phone_number": "(267) 474-4395",
      "pharmacy_id": 2
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "CVS",
      "user_id": 13,
      "join_code": "CF1667",
      "city": "Philadelphia",
      "street_address": "123 newark avenue",
      "zip_code": "19929",
      "state": "Pennsylvania"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "Right Aide",
      "user_id": 14,
      "join_code": "681593",
      "city": "Trenton",
      "street_address": "456 Welch Street",
      "zip_code": "12342",
      "state": "New Jersey"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "Woodlands",
      "user_id": 23,
      "join_code": "2E1546",
      "city": "South Helenbury",
      "street_address": "0317 Sandra Lake Suite 459",
      "zip_code": "43520",
      "state": "Tennessee"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "Marshall Group",
      "user_id": 47,
      "join_code": "AABEC9",
      "city": "Kathleenbury",
      "street_address": "42609 Ann Vista Suite 462",
      "zip_code": "09028",
      "state": "Washington"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "wallbrowns",
      "user_id": 70,
      "join_code": "493F3D",
      "city": "South Jessicafort",
      "street_address": "14192 Joseph Lock Apt. 633",
      "zip_code": "39607",
      "state": "Kentucky"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "Giant Pharmacy",
      "user_id": 421,
      "join_code": "02A02B",
      "city": "Philadelphia",
      "street_address": "134 Bustleton Ave",
      "zip_code": "19115",
      "state": "PA"
    }
  },
  {
    "model": "pharmacy.pharmacyprofile",
    "fields": {
      "pharmacy_name": "cvs",
      "user_id": 427,
      "join_code": "7DE91A",
      "city": "sadsdas",
      "street_address": "sdsdas",
      "zip_code": "ddddd",
      "state": "dsasd"
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Nicholas",
      "last_name": "George",
      "pharmacy_id": 1,
      "user_id": 15
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Rick",
      "last_name": "Smith",
      "pharmacy_id": 2,
      "user_id": 16
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Randall",
      "last_name": "Navarro",
      "pharmacy_id": 1,
      "user_id": 302
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Christina",
      "last_name": "Jones",
      "pharmacy_id": 1,
      "user_id": 303
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Richard",
      "last_name": "Richmond",
      "pharmacy_id": 1,
      "user_id": 304
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Teresa",
      "last_name": "Martinez",
      "pharmacy_id": 2,
      "user_id": 325
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Leroy",
      "last_name": "Crane",
      "pharmacy_id": 2,
      "user_id": 326
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Rachel",
      "last_name": "Leach",
      "pharmacy_id": 2,
      "user_id": 327
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Logan",
      "last_name": "Mason",
      "pharmacy_id": 3,
      "user_id": 348
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Mark",
      "last_name": "Fleming",
      "pharmacy_id": 3,
      "user_id": 349
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Gregory",
      "last_name": "Odonnell",
      "pharmacy_id": 3,
      "user_id": 350
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Brian",
      "last_name": "Combs",
      "pharmacy_id": 4,
      "user_id": 371
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Mikayla",
      "last_name": "Welch",
      "pharmacy_id": 4,
      "user_id": 372
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "William",
      "last_name": "Carlson",
      "pharmacy_id": 4,
      "user_id": 373
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Christopher",
      "last_name": "Warner",
      "pharmacy_id": 5,
      "user_id": 394
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Vincent",
      "last_name": "Williams",
      "pharmacy_id": 5,
      "user_id": 395
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Leslie",
      "last_name": "Johnson",
      "pharmacy_id": 5,
      "user_id": 396
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Thomas",
      "last_name": "Shelby",
      "pharmacy_id": 3,
      "user_id": 420
    }
  },
  {
    "model": "pharmacy.pharmacistprofile",
    "fields": {
      "first_name": "Jared",
      "last_name": "Mcain",
      "pharmacy_id": 6,
      "user_id": 423
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 1,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 50,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 2,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 75,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 80,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 99,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 60,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 10,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "low_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 80,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 90,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 3,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 4,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 5,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ACETAMINOPHEN",
      "brand": "Pain Reliever Extra Strength",
      "description": "",
      "dosage": "Directions do not take more than directed adults and children 12 years and over take 2 gelcaps every 6 hours while symptoms last do not take more than 6 gelcaps in 24 hours, unless directed by a doctor do not take for more than 10 days unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROCODONE BITARTRATE AND ACETAMINOPHEN",
      "brand": "Hydrocodone Bitartrate and Acetaminophen",
      "description": "DESCRIPTION Hydrocodone bitartrate and acetaminophen, USP is available in tablet form for oral administration. It is affected by light. It has the following structural formula: Acetaminophen, 4' -hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "Initial Dosage Initiating Treatment with Hydrocodone Bitartrate and Acetaminophen Tablets 2.5 mg/325 mg The usual adult dosage is one or two tablets every four to six hours as needed for pain. It is safer to underestimate a patient\u2019s 24-hour hydrocodone bitartrate and acetaminophen tablets dosage than to overestimate the 24-hour hydrocodone bitartrate and acetaminophen tablets dosage and manage an adverse reaction due to overdose. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking hydrocodone bitartrate and acetaminophen tablets, there are a variety of factors that should be considered, including the dose of hydrocodone bitartrate and acetaminophen tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALBUTEROL SULFATE",
      "brand": "Albuterol Sulfate HFA",
      "description": "Albuterol sulfate has the chemical name \u03b1 1 -[( tert -butylamino)methyl]-4-hydroxy- m -xylene-\u03b1, \u03b1\u2032-diol sulfate (2:1)(salt) and the following chemical structure: Albuterol sulfate is a white crystalline powder with a molecular weight of 576.7, and the empirical formula is (C 13 H 21 NO 3 ) 2 \u2022H 2 SO 4 . Each canister contains a microcrystalline suspension of albuterol sulfate in propellant HFA\u2011134a (1,1,1,2\u2011tetrafluoroethane). Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "dosage": "2 DOSAGE AND ADMINISTRATION For oral inhalation only. ( 2 ) Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older: 2 inhalations by oral inhalation every 4 to 6 hours. ( 2.2 ) Priming information: Prime Albuterol Sulfate HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALENDRONATE SODIUM",
      "brand": "Binosto",
      "description": "11 DESCRIPTION BINOSTO (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Alendronate sodium is chemically described as (4 amino-1-hydroxybutylidene) bisphosphonic acid, monosodium salt, trihydrate. Once the effervescent tablet is dissolved in water, the alendronate sodium is present in a citrate-buffered solution of pH 4.8 to 5.4.",
      "dosage": "Take BINOSTO upon arising for the day and at least 30 minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved effervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [see Warnings and Precautions (5.1) ]. 2.4 Recommendations for Calcium and Vitamin D Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [see Warnings and Precautions (5.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALLOPURINOL",
      "brand": "Allopurinol",
      "description": "11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate.",
      "dosage": "2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ALPRAZOLAM",
      "brand": "Alprazolam",
      "description": "11 DESCRIPTION Alprazolam tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-\u03b1] [1,4] benzodiazepine. In addition, the 0.5 mg tablet contains FD&C Yellow # 6 aluminum lake and the 1 mg tablet contains FD&C Blue No.",
      "dosage": "Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. 2.2 Dosage in Panic Disorder The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMOXICILLIN",
      "brand": "Amoxicillin",
      "description": "Amoxicillin Tablets, USP: Each film coated tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Amoxicillin for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125 mg, 200 mg, 250 mg, and 400 mg reconstituted suspension contains 0.30 mEq (6.95 mg) of sodium.",
      "dosage": "Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age Infection Severity Dosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. 2.3 Dosing for H. pylori Infection Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AMLODIPINE BESYLATE",
      "brand": "Amlodipine Besylate",
      "description": "11 DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (\u00b1)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Amlodipine besylate tablets USP are formulated as tablets equivalent to 2.5 mg, 5 mg and 10 mg of amlodipine for oral administration.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. Angina The recommended dose for chronic stable or vasospastic angina is 5 to 10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency. Doses in excess of 5 mg daily have not been studied in pediatric patients [see CLINICAL PHARMACOLOGY (12.4) , CLINICAL STUDIES (14.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ARIPIPRAZOLE",
      "brand": "Aripiprazole",
      "description": "11 DESCRIPTION Aripiprazole is an atypical antipsychotic drug that is available as Aripiprazole Tablets, USP. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23 H 27 Cl 2 N 3 O 2 and its molecular weight is 448.38.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia \u2013 adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia \u2013 adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Irritability associated with autistic disorder \u2013 pediatric patients (2.4) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette\u2019s disorder \u2013 (2.5) Patients <50 kg 2 mg/day 5 mg/day 10 mg/day Patients \u226550 kg 2 mg/day 10 mg/day 20 mg/day \u2022Oral formulations: Administer once daily without regard to meals (2) \u2022Known CYP2D6 poor metabolizers: Half of the usual dose (2.7) 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on Day 8.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATENOLOL",
      "brand": "Atenolol",
      "description": "DESCRIPTION Atenolol, a synthetic, beta 1 -selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4-[2\u2019-hydroxy-3\u2019-[(1-methylethyl)amino]propoxy]-. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37\u00b0C and a log partition coefficient (octanol/water) of 0.23. Atenolol is available as 25, 50 or 100 mg tablets for oral administration.",
      "dosage": "If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance (mL/min/1.73m 2 ) Atenolol Elimination Half-Life (h) Maximum Dosage 15-35 16-27 50 mg daily < 15 > 27 25 mg daily Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ATORVASTATIN CALCIUM",
      "brand": "Atorvastatin calcium",
      "description": "11 DESCRIPTION Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Atorvastatin calcium USP is (\u03b2R, \u03b4R)-2-(p-fluorophenyl)-\u03b2,\u03b4-dihydroxy-5-isopropyl-3-phenyl-4(phenylcarbamoyl)pyrrole-l-heptanaote (1:2), trihydrate. The molecular formula of atorvastatin calcium USP is C 66 H 68 CaF 2 N 4 O 10 .3H 2 O and its molecular weight is 1209.41.",
      "dosage": "2.1 Important Dosage Information Take atorvastatin calcium tablets orally once daily at any time of the day, with or without food. 2.2 Recommended Dosage in Adult Patients The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily. 2.4 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HoFH The recommended starting dosage of atorvastatin calcium tablets are 10 mg to 20 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "AZITHROMYCIN",
      "brand": "Azithromycin",
      "description": "11 DESCRIPTION Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.",
      "dosage": "Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. 2.1 Adult Patients [see Indications and Usage (1.1) and Clinical Pharmacology (12.3) ] Infection* Recommended Dose/Duration of Therapy Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic obstructive pulmonary disease 500 mg once daily for 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) One single 1 gram dose Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose * DUE TO THE INDICATED ORGANISMS [see Indications and Usage (1.1) ] Azithromycin tablets can be taken with or without food.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BACLOFEN INJECTION",
      "brand": "Gablofen",
      "description": "11 DESCRIPTION GABLOFEN (baclofen injection) is a muscle relaxant and antispastic. Baclofen's pharmacological class is a gamma-aminobutyric acid (GABA) ergic agonist. Baclofen's chemical name is 4-amino-3-(4-chlorophenyl) butanoic acid, and its structural formula is: Baclofen C 10 H 12 ClNO 2 Baclofen is a white to off-white powder, with a molecular weight of 213.66.",
      "dosage": "2.2 Screening Phase Prior to pump implantation and initiation of chronic infusion of GABLOFEN, patients must demonstrate a positive clinical response to a GABLOFEN bolus dose administered intrathecally in a screening trial. 2.5 Dose Titration Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved.",
      "stock": 100,
      "route": "INTRATHECAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BENAZEPRIL HYDROCHLORIDE",
      "brand": "Benazepril Hydrochloride",
      "description": "Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H -1-(3S)-benzazepine-1-acetic acid monohydrochloride; its structural formula is Its empirical formula is C 24 H 28 N 2 O 5 \u2022HCl and its molecular weight is 460.96. Benazepril hydrochloride is supplied as film-coated tablets containing 5 mg, 10 mg, 20 mg, and 40 mg of benazepril hydrochloride for oral administration. Benazepril hydrochloride tablets USP, 5 mg, 10 mg, 20 mg and 40 mg meet USP Dissolution Test 2.",
      "dosage": "\u2022 Renal Impairment: Initiate with 5 mg once daily in patients with GFR <30 mL/min/1.73 m 2 (serum creatinine >3 mg/dL) ( 2 .2) 2.1 Recommended Dosage ADULTS The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. Use with diuretics in adults The recommended starting dose of benazepril hydrochloride tablets in a patient on a diuretic is 5 mg once daily. 2.2 Dose Adjustment for Renal Impairment For adults with a GFR < 30 mL/min/1.73 m 2 (serum creatinine > 3 mg/dL), the recommended initial dose is 5 mg benazepril hydrochloride tablets once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BISOPROLOL FUMARATE",
      "brand": "Bisoprolol fumarate",
      "description": "It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. Bisoprolol fumarate tablets are available as 5 and 10 mg tablets for oral administration. The 5 mg tablets also contain Red Iron Oxide.",
      "dosage": "DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate tablets must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUPROPION HYDROCHLORIDE",
      "brand": "Bupropion Hydrochloride XL",
      "description": "11 DESCRIPTION Bupropion Hydrochloride USP, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. The structural formula is: Bupropion Hydrochloride Extended-Release Tablets USP (XL) are supplied for oral administration as 150 mg and 300 mg white to pale yellow extended-release tablets.",
      "dosage": "2.2 Dosage for Major Depressive Disorder (MDD) The recommended starting dose for MDD is 150 mg once daily in the morning. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). 2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUSPIRONE HYDROCHLORIDE",
      "brand": "Buspirone Hydrochloride",
      "description": "421.96 Each tablet, for oral administration, contains 5 mg, 7.5 mg, 10 mg, 15 mg or 30 mg of buspirone hydrochloride, USP (equivalent to 4.6 mg, 6.9 mg, 9.1 mg, 13.7 mg and 27.4 mg of buspirone free base, respectively). Thus, a single 15 mg tablet can provide the following doses: 15 mg (entire tablet), 10 mg (two-thirds of a tablet), 7.5 mg (one-half of a tablet), or 5 mg (one-third of a tablet). A single 30 mg tablet can provide the following doses: 30 mg (entire tablet), 20 mg (two-thirds of a tablet), 15 mg (one-half of a tablet), or 10 mg (one-third of a tablet).",
      "dosage": "To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. Use of Buspirone with (Reversible) MAOIs, Such as Linezolid or Methylene Blue Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE",
      "brand": "Butalbital, Acetaminophen, Caffeine and Codeine Phosphate",
      "description": "11 DESCRIPTION Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are supplied in capsule form for oral administration. Each capsule contains: Butalbital, USP 50 mg Acetaminophen, USP 325 mg Caffeine, USP 40 mg Codeine phosphate, USP 30 mg Butalbital (5-allyl-5-isobutylbarbituric acid), is a short-to intermediate-acting barbiturate. It has the following structural formula: C 11 H 16 N 2 O 3 MW 224.26 Acetaminophen (4'hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic.",
      "dosage": "2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules, there are a variety of factors that should be considered, including the dose of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. For patients on Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "brand": "CAPTOPRIL AND HYDROCHLOROTHIAZIDE",
      "description": "DESCRIPTION Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Captopril, USP is a white to off-white crystalline powder with characteristic sulfide-like odor; it is freely soluble in water, ethanol, methanol, chloroform, isopropyl alcohol and methylene chloride and soluble in ethyl acetate. Freely soluble in N,N-Dimethylformamide, in n-Butylamine and in diluted solutions of alkali hydroxides.",
      "dosage": "For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used. In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg. Captopril and hydrochlorothiazide tablets should be taken one hour before meals. When concomitant diuretic therapy is required in patients with severe renal impairment, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CARVEDILOL",
      "brand": "Carvedilol",
      "description": "11 DESCRIPTION Carvedilol is a nonselective \u03b2-adrenergic blocking agent with \u03b1 1 -blocking activity. It is (\u00b1)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. Carvedilol is a racemic mixture with the following structure: Carvedilol, USP is a white to almost white crystalline powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .",
      "dosage": "Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). The recommended starting dose of carvedilol tablets are 6.25 mg twice daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFDINIR",
      "brand": "Cefdinir",
      "description": "DESCRIPTION Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6\u03b1,7\u03b2 (Z)]]-7-[[(2-amino-4 thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid.",
      "dosage": "DOSAGE & ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. For pediatric patients with a creatinine clearance of < 30 mL/min/1.73 m 2 , the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CEFUROXIME AXETIL",
      "brand": "Cefuroxime axetil",
      "description": "Cefuroxime axetil is a semisynthetic, cephalosporin antibacterial drug for oral administration. The chemical name of cefuroxime axetil (1-(acetyloxy) ethyl ester of cefuroxime) is ( RS )-1 hydroxyethyl (6 R ,7 R )-7-[2-(2-furyl)glyoxyl-amido]-3-(hydroxymethyl)-8-oxo-5-thia-1 azabicyclo[4.2.0]-oct-2-ene-2-carboxylate, 72-( Z )-( O -methyl-oxime), 1-acetate 3-carbamate. Cefuroxime axetil is in the amorphous form and has the following structural formula: Cefuroxime axetil tablets, USP are film-coated and contain the equivalent of 250 or 500 mg of cefuroxime as cefuroxime axetil.",
      "dosage": "Pediatric patients (aged 13 years and older) who cannot swallow the cefuroxime axetil tablets whole should receive cefuroxime axetil for oral suspension because the tablet has a strong, persistent bitter taste when crushed [see Dosage and Administration ( 2.2 )]. 2.2 Dosage for Cefuroxime axetil Tablets Administer cefuroxime axetil tablets as described in the dosage guidelines table below with or without food. 2.5 Dosage in Patients with Impaired Renal Function A dosage interval adjustment is required for patients whose creatinine clearance is less than 30 mL/min, as listed in Table 4 below, because cefuroxime is eliminated primarily by the kidney [see Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CELECOXIB",
      "brand": "CELECOXIB",
      "description": "DESCRIPTION Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. Its molecular formula is C 17 H 14 F 3 N 3 O 2 S, and it has the following chemical structure: Celecoxib USP is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib USP is hydrophobic (log P is 3.5) and is soluble in ethanol and in methylene chloride, practically insoluble in water.",
      "dosage": "For patients >25 kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce. The use of celecoxib in patients with severe hepatic impairment is not recommended [ see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CETIRIZINE HYDROCHLORIDE TABLETS",
      "brand": "cetirizine hydrochloride",
      "description": "",
      "dosage": "Directions adults and children 6 years and over one 10 mg tablet once daily; do not take more than one 10 mg tablet in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CIPROFLOXACIN",
      "brand": "ciprofloxacin",
      "description": "DESCRIPTION Ciprofloxacin ophthalmic solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid.",
      "dosage": "DOSAGE AND ADMINISTRATION Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours.",
      "stock": 100,
      "route": "OPHTHALMIC",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CITALOPRAM",
      "brand": "Citalopram",
      "description": "11 DESCRIPTION Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (\u00b1)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3\u00addihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula: The molecular formula is C 20 H 22 BrFN 2 O and its molecular weight is 405.35. Citalopram hydrobromide, USP occurs as a fine, white to off-white powder.",
      "dosage": "2.1 Recommended Dosage Administer citalopram tablets once daily, with or without food, at an initial dosage of 20 mg once daily, with an increase to a maximum dosage of 40 mg once daily at an interval of no less than one week. 2.3 Recommended Dosage for Specific Populations The maximum recommended dosage of citalopram tablets for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )] . 2.4 Dosage Modifications with Concomitant Use of CYP2C19 Inhibitors The maximum recommended dosage of citalopram tablets when used concomitantly with a CYP2C19 inhibitor is 20 mg once daily [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLINDAMYCIN PHOSPHATE",
      "brand": "Clindamycin Phosphate",
      "description": "DESCRIPTION Clindamycin phosphate topical lotion, 1% contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.",
      "dosage": "DOSAGE AND ADMINISTRATION Apply a thin film of clindamycin phosphate topical lotion twice daily to affected area. Lotion: Shake well immediately before using. Keep all liquid dosage forms in containers tightly closed.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLONAZEPAM",
      "brand": "Clonazepam",
      "description": "DESCRIPTION Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing \u039b containing 0.5 mg of clonazepam and unscored tablets with debossing \u039b and \u039b containing 1 mg or 2 mg of clonazepam respectively. Each 66 67 69 tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder.",
      "dosage": "Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CLOPIDOGREL BISULFATE",
      "brand": "Clopidogrel",
      "description": "11 DESCRIPTION Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y 12 ADP platelet receptors. Chemically it is methyl (+)-( S )-\u03b1-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4 H )-\u00adacetate sulfate (1:1). The structural formula is as follows: Clopidogrel bisulfate USP is a white to off-white powder.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1) ] . 2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "brand": "CYCLOBENZAPRINE HYDROCHLORIDE",
      "description": "DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N \u2022 HCl and a molecular weight of 311.9. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake.",
      "dosage": "DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DAPAGLIFLOZIN",
      "brand": "FARXIGA",
      "description": "11 DESCRIPTION Dapagliflozin, an inhibitor of SGLT2, is described chemically as D-glucitol, 1,5-anhydro-1- C -[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1 S )-, compounded with (2 S )-1,2-propanediol, hydrate (1:1:1). The empirical formula is C 21 H 25 ClO 6 \u2022C 3 H 8 O 2 \u2022H 2 O and the molecular weight is 502.98. The structural formula is: FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate.",
      "dosage": "2 DOSAGE AND ADMINISTRATION \u2022 Assess volume status and correct volume depletion before initiating. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ] . Table 1: Recommended Dosage eGFR (mL/min/1.73 m 2 ) Recommended Dose eGFR 45 or greater To improve glycemic control, the recommended starting dose is 5 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DESVENLAFAXINE SUCCINATE",
      "brand": "Pristiq Extended-Release",
      "description": "11 DESCRIPTION PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine is designated RS -4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C 16 H 25 NO 2 (free base) and C 16 H 25 NO 2 \u2219C 4 H 6 O 4 \u2219H 2 O (succinate monohydrate). Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&C yellow #6.",
      "dosage": "In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses. The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.5) and Warnings and Precautions (5.7) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIAZEPAM",
      "brand": "Diazepam",
      "description": "The molecular formula is C 16 H 13 ClN 2 O and the molecular weight is 284.7. The structural formula is as follows: Diazepam is available for oral administration as tablets containing 2 mg, 5 mg or 10 mg diazepam, USP. 10 Aluminum Lake and FD&C Blue No.",
      "dosage": "2 mg to 10 mg, 3 or 4 times daily Adjunctively in Convulsive Disorders. 2 mg to 2.5 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICLOFENAC SODIUM",
      "brand": "Diclofenac Sodium",
      "description": "",
      "dosage": "Directions Use up to 21 days unless directed by your doctor Not for strains, sprains, bruises or sports injuries. This product has not been shown to work for these types of injuries. Daily Per Dose For your arthritis pain: Use 4 times per day every day Do not use on more than 2 body areas at the same time Use ENCLOSED DOSING CARD to measure a dose For each upper body area (hand, wrist, or elbow) \u2013 Squeeze out 2.25 inches (2 grams) For each lower body area (foot, ankle or knee) \u2013Squeeze out 4.5 inches (4 grams) Read the enclosed User Guide for complete instructions: use only as directed do not use more than directed or for longer than directed apply only to clean, dry skin that does not have any cuts, open wounds, infections or rashes do not apply in same area as any other product do not apply with external heat such as heating pad do not apply a bandage over the treated area store ENCLOSED DOSING CARD with your Diclofenac Sodium Topical Gel, 1% product.",
      "stock": 100,
      "route": "TOPICAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DICYCLOMINE HYDROCHLORIDE",
      "brand": "Dicyclomine hydrochloride",
      "description": "11 DESCRIPTION Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available as: Dicyclomine hydrochloride capsules, USP for oral use containing 10 mg dicyclomine hydrochloride, USP. Dicyclomine hydrochloride 10 mg capsules contain the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Capsule shells contain FD&C Blue No.1, FD&C Red No.40, gelatin, purified water, and sodium lauryl sulfate.",
      "dosage": "Dosage for dicyclomine hydrochloride capsules must be adjusted to individual patient needs (2) . After a week treatment with the starting dose, the dose may be escalated to 40 mg four times a day, unless side effects limit dosage escalation Discontinue dicyclomine hydrochloride if efficacy not achieved or side effects require doses less than 80 mg per day after two weeks of treatment 2.1 Oral Dosage and Administration in Adults The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIGOXIN",
      "brand": "Digoxin",
      "description": "11 DESCRIPTION Digoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. The term \u201cdigitalis\u201d is used to designate the whole group of glycosides.",
      "dosage": "2.2 Loading Dosing Regimen in Adults and Pediatric Patients For adults and pediatric patients if a loading dosage is to be given, administer half the total loading dose initially, then \u00bc the loading dose every 6-8 hours twice, with careful assessment of clinical response and toxicity before each dose. The recommended starting maintenance dose in adults and pediatric patients over 10 years old with normal renal function is given in Table 2. Recommended Maintenance Dose (in micrograms given once daily) of Digoxin in Pediatric Patients Over 10 Years Old and Adults by Lean Body Weight and by Renal Functiona Corrected Creatinine Clearance b Lean Body Weight d Number of Days Before Steady State Achievedc kg 40 50 60 70 80 90 100 10 mL/min 62.5* 125 125 187.5 187.5 187.5 250 19 20 mL/min 125 125 125 187.5 187.5 250 250 16 30 mL/min 125 125 187.5 187.5 250 250 312.5 14 40 mL/min 125 187.5 187.5 250 250 312.5 312.5 13 50 mL/min 125 187.5 187.5 250 250 312.5 312.5 12 60 mL/min 125 187.5 250 250 312.5 312.5 375 11 70 mL/min 187.5 187.5 250 250 312.5 375 375 10 80 mL/min 187.5 187.5 250 312.5 312.5 375 437.5 9 90 mL/min 187.5 250 250 312.5 375 437.5 437.5 8 100 mL/min 187.5 250 312.5 312.5 375 437.5 500 7 a Doses are rounded to the nearest dose possible using whole digoxin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DILTIAZEM HYDROCHLORIDE",
      "brand": "diltiazem hydrochloride",
      "description": "DESCRIPTION Diltiazem hydrochloride is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1, 5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride,(+)-cis-. The chemical structure is: USP Dissolution pending.",
      "dosage": "Individual patients may respond to higher doses of up to 480 mg once daily. Antihypertensives : Diltiazem hydrochloride extended-release capsules, USP have an additive antihypertensive effect when used with other antihypertensive agents. Therefore, the dosage of diltiazem hydrochloride extended-release capsules, USP or the concomitant antihypertensives may need to be adjusted when adding one to the other.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIPHENHYDRAMINE HCL",
      "brand": "Childrens Allergy Relief",
      "description": "",
      "dosage": "Directions \u25a0 if needed, take every 4-6 hours \u25a0 do not take more than 6 doses in 24-hours children under 4 years of age Do not use children 4 to under 6 years of age Do not use unless directed by a doctor children 6 to under 12 years of age 1 to 2 teaspoonfuls (5 ml to 10 ml)",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DIVALPROEX SODIUM",
      "brand": "Divalproex Sodium",
      "description": "Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid. Inactive Ingredients: ammonium hydroxide, colloidal anhydrous silica, colloidal silicon dioxide, dibutyl sebacate, ethylcellulose, hydroxyethyl cellulose, hypromellose, oleic acid, polydextrose, polyethylene glycol, silicified microcrystalline cellulose, titanium dioxide and triacetin.",
      "dosage": "Although doses other than 1,000 mg once daily of divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of divalproex sodium delayed-release tablets in these patients is 500-1,000 mg/day. 2.4 Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving divalproex sodium delayed-release tablets, divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of divalproex sodium delayed-release tablets (Table 1). Dose Conversion Divalproex Sodium Delayed-Release Tablets Divalproex Sodium Extended-Release Tablets Total Daily Dose (mg) (mg) 500 These total daily doses of divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of divalproex sodium extended-release tablets because the required dosing strengths of divalproex sodium extended-release tablets are not available.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DOXYCYCLINE",
      "brand": "doxycycline",
      "description": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Doxycycline is an antibacterial drug synthetically derived from oxytetracycline, and is available as capsules of doxycycline hyclate for oral administration. The structural formula of doxycycline monohydrate is with a molecular formula of C 22 H 24 N 2 O 8 \u2219H 2 O and a molecular weight of 462.46.",
      "dosage": "Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice a day for 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "DULAGLUTIDE",
      "brand": "TRULICITY",
      "description": "11 DESCRIPTION Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37).",
      "dosage": "2 DOSAGE AND ADMINISTRATION Adult Dosage ( 2.1 ) Recommended starting dosage is 0.75 mg injected subcutaneously once weekly. 2.1 Adult Dosage The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ENALAPRIL MALEATE",
      "brand": "Enalapril Maleate",
      "description": "DESCRIPTION Enalapril maleate is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Its molecular formula is C 20 H 28 N 2 O 5 \u2219C 4 H 4 O 4, and its structural formula is: Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.",
      "dosage": "DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets, USP. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure , WARNINGS and PRECAUTIONS, Drug Interactions ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESCITALOPRAM ORAL",
      "brand": "Escitalopram Oral Solution",
      "description": "11 DESCRIPTION Escitalopram Oral Solution, USP contains escitalopram oxalate, an orally administered selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3-(dimethyl-amino)propyl]-1-( p -fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula: The molecular formula is C 20 H 21 FN 2O \u2022 C 2 H 2 O 4 and the molecular weight is 414.40.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram, reduce dose gradually whenever possible ( 2.5 ) 2.1 Major Depressive Disorder Adults The recommended dosage of escitalopram in adults is 10 mg once daily. 2.5 Recommended Dosage for Specific Populations The recommended dosage for most elderly patients and patients with hepatic impairment is 10 mg once daily [ see Use in Specific Populations ( 8.5 , 8.6 ) ]. 2.6 Discontinuation of Treatment with Escitalopram Symptoms associated with discontinuation of escitalopram and other SSRIs and SNRIs have been reported [ see Warnings and Precautions (5.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESOMEPRAZOLE MAGNESIUM",
      "brand": "Acid Reducer",
      "description": "",
      "dosage": "Directions adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days may take 1 to 4 days for full effect 14-Day Course of Treatment \u2022 swallow 1 tablet with a glass of water before eating in the morning \u2022 take every day for 14 days \u2022 do not take more than 1 tablet a day \u2022 swallow whole. Do not crush or chew capsules. \u2022 do not use for more than 14 days unless directed by your doctor Repeated 14-Day Courses (if needed) \u2022 you may repeat a 14-day course every 4 months \u2022 do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor before use.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ESZOPICLONE",
      "brand": "Eszopiclone",
      "description": "11 DESCRIPTION Eszopiclone is a hypnotic agent/nonbenzodiazepine hypnotic agent that is a pyrrolopyrazine derivative of the cyclopyrrolone class. The chemical name of eszopiclone is (+)-4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5 H pyrrolo[3,4- b ]pyrazin-5-(S)-yl ester. In addition, both the 1 mg and 3 mg tablets contain FD&C Blue #2/indigo carmine aluminium lake.",
      "dosage": "May increase dose if clinically indicated, to a maximum of 3 mg ( 2.1 ) \u2022 Geriatric or debilitated patients: Dose should not exceed 2 mg ( 2.2 ) \u2022 Patients with severe hepatic impairment, or taking potent CYP3A4 inhibitors: Dose should not exceed 2 mg ( 2.3 ) \u2022 Do not take with or immediately after a meal ( 2.5 ) 2.1 Dosage in Adults The recommended starting dose is 1 mg. Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of eszopiclone tablets should not exceed 3 mg, once daily immediately before bedtime [ see Warnings and Precautions (5.6) ]. 2.3 Patients with Severe Hepatic Impairment, or Taking Potent CYP3A4 Inhibitors In patients with severe hepatic impairment, or in patients coadministered eszopiclone tablets with potent CYP3A4 inhibitors, the total dose of eszopiclone tablets should not exceed 2 mg [ see Warnings and Precautions (5.7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FENTANYL CITRATE",
      "brand": "Fentanyl Citrate",
      "description": "Fentanyl citrate is chemically identified as N -(1-Phenethyl-4-piperidyl)propionanilide citrate (1:1) with the following structural formula: C 22 H 28 N 2 O \u2022 C 6 H 8 O 7 Molecular Weight is 528.59 Each mL contains fentanyl citrate equivalent to 50 mcg (0.05 mg) fentanyl base in Water for Injection. Sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The pH range is 4.0 to 7.5.",
      "dosage": "For use in more major surgical procedures, in addition to adequate analgesia, may abolish some of the stress response. Maintenance dosage [ranging from 25 mcg (0.025 mg) (0.5 mL) to one half the initial loading dose] as needed based on vital signs indicative of stress and lightening of analgesia. As a General Anesthetic As a technique to attenuate the responses to surgical stress without the use of additional anesthetic agents, doses of 50 to 100 mcg/kg (0.05 to 0.1 mg/kg) (1 to 2 mL/kg) may be administered with oxygen and a muscle relaxant.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FEXOFENADINE HCL",
      "brand": "Fexofenadine HCL",
      "description": "",
      "dosage": "Directions adults and children 12 years of age and over: take one 180 mg tablet with water every once a day; do not take more than 1 tablet in 24 hours children under 12 years of age: do not use adults 65 years of age and older: ask a doctor consumers with kidney disease: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FINASTERIDE",
      "brand": "Finasteride",
      "description": "11 DESCRIPTION Finasteride tablets USP, 1 mg contains finasteride as the active ingredient. Finasteride is 4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5\u03b1, 17\u03b2)-. Its structural formula is: Finasteride is a white crystalline powder with a melting point near 250\u00b0 C. It is freely soluble in chloroform and in lower alcohol solvents but is practically insoluble in water.",
      "dosage": "The recommended dose of finasteride tablets USP is one tablet (1 mg) taken once daily. In general, daily use for three months or more is necessary before benefit is observed. Continued use is recommended to sustain benefit, which should be re-evaluated periodically.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUCONAZOLE",
      "brand": "Fluconazole",
      "description": "DESCRIPTION Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. Fluconazole is designated chemically as 2,4-difluoro-\u03b1,\u03b1 1 -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of C 13 H 12 F 2 N 6 O and molecular weight of 306.3. The structural formula is: Fluconazole USP is a white crystalline solid which is slightly soluble in water and saline.",
      "dosage": "DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of fluconazole for vaginal candidiasis is 150 mg as a single oral dose. The daily dose of fluconazole for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient\u2019s response to therapy. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUOXETINE HYDROCHLORIDE",
      "brand": "Fluoxetine",
      "description": "11 DESCRIPTION Fluoxetine capsules, USP are a selective serotonin reuptake inhibitor for oral administration. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem \u00ae , fluoxetine hydrochloride). In addition, 20 mg capsules also contains D&C Yellow #10 and 10 mg capsules also contains FD&C Yellow #6.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder ( 2.5 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 ) 2.1 Major Depressive Disorder Initial Treatment Adult \u2014 Initiate fluoxetine 20 mg/day orally in the morning. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "FLUTICASONE PROPIONATE",
      "brand": "FLOVENT DISKUS",
      "description": "11 DESCRIPTION FLOVENT DISKUS inhalation powder is a dry powder inhaler for oral inhalation. The active component of FLOVENT DISKUS 50 mcg, FLOVENT DISKUS 100 mcg, and FLOVENT DISKUS 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S- (fluoromethyl) 6\u03b1,9-difluoro-11\u03b2,17-dihydroxy-16\u03b1-methyl-3-oxoandrosta-1,4-diene-17\u03b2-carbothioate, 17-propionate and the following chemical structure: Fluticasone propionate is a white powder with a molecular weight of 500.6, and the empirical formula is C 25 H 31 F 3 O 5 S. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Each blister on the strip contains a white powder mix of micronized fluticasone propionate (50, 100, or 250 mcg) in 12.5 mg of formulation containing lactose monohydrate (which contains milk proteins).",
      "dosage": "2.2 Recommended Dosage Adult and Adolescent Patients Aged 12 Years and Older The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients\u2019 current control of asthma symptoms and risk of future exacerbation. The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. For patients aged 4 to 11 years not on an ICS, the recommended starting dosage is 50 mcg twice daily, approximately 12 hours apart.",
      "stock": 100,
      "route": "RESPIRATORY (INHALATION)",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GABAPENTIN",
      "brand": "Gabapentin",
      "description": "11 DESCRIPTION The active ingredient in Gabapentin Capsules USP is gabapentin, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid. The molecular formula of gabapentin is C 9 H 17 NO 2 and the molecular weight is 171.24. The structural formula of gabapentin is: Gabapentin is a white to off-white crystalline solid with a pK a1 of 3.7 and a pK a2 of 10.7.",
      "dosage": "2 DOSAGE AND ADMlNlSTRATION Postherpetic Neuralgia (2.1) Dose can be titrated up as needed to a dose of 1800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures (2.2) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 ) 2.1 Dosage for Postherpetic Neuralgia In adults with postherpetic neuralgia, Gabapentin may be initiated on Day 1 as a single 300 mg dose, on Day 2 as 600 mg/day (300 mg two times a day), and on Day 3 as 900 mg/day (300 mg three times a day). Administer Gabapentin three times a day using 300 mg or 400 mg capsules.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GEMFIBROZIL",
      "brand": "Gemfibrozil",
      "description": "DESCRIPTION Gemfibrozil, USP is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil.",
      "dosage": "DOSAGE AND ADMINISTRATION The recommended dose for adults is 1,200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIMEPIRIDE",
      "brand": "Glimepiride",
      "description": "11 DESCRIPTION Glimepiride tablets USP, are an oral sulfonylurea that contains the active ingredient glimepiride USP. Chemically, glimepiride USP is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido) ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white to almost white powder, soluble in dimethyl formamide, sparingly soluble in methylene chloride, practically insoluble in water.",
      "dosage": "The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5 , 8.6) ]. After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient\u2019s glycemic response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "GLIPIZIDE",
      "brand": "Glipizide",
      "description": "The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[ p -[2-(5-methylpyrazine-carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C 21 H 27 N 5 O 4 S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. Glipizide Tablets USP for oral use are available in 5 and 10 mg strengths.",
      "dosage": "In addition to the usual monitoring of urinary glucose, the patient\u2019s blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood-glucose-lowering response after an initial period of effectiveness. The maximum recommended total daily dose is 40 mg. When transferring patients from insulin to glipizide, the following general guidelines should be considered: For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "HYDROXYCHLOROQUINE SULFATE",
      "brand": "Hydroxychloroquine Sulfate",
      "description": "DESCRIPTION Hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-[[4-[(7-Chloro-4-quinolyl) amino]pentyl] ethylamino]ethanol sulfate (1:1). Its structural formula is: The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O.H 2 SO 4 .",
      "dosage": "Treatment of Uncomplicated Malaria Adults: 800 mg (620 mg base) followed by 400 mg (310 mg base) at 6 hours, 24 hours and 48 hours after the initial dose (total 2000 mg hydroxychloroquine sulfate or 1550 mg base). Maintenance adult dosage: When a good response is obtained, the dosage may be reduced by 50 percent and continued at a maintenance level of 200 mg to 400 mg (155 to 310 mg base) daily, administered as a single daily dose or in two divided doses. Corticosteroids and salicylates may be used in conjunction with Hydroxychloroquine sulfate tablets, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of Hydroxychloroquine sulfate tablets has been achieved.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "IBUPROFEN",
      "brand": "Ibuprofen Dye Free",
      "description": "",
      "dosage": "Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN ASPART",
      "brand": "NOVOLOG",
      "description": "11 DESCRIPTION Insulin aspart is a rapid-acting human insulin analog homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker's yeast). Insulin aspart has the empirical formula C 256 H 381 N 65 0 79 S 6 and a molecular weight of 5825.8 Da. NOVOLOG has a pH of 7.2-7.6.",
      "dosage": "\u2022 Continuous Subcutaneous Infusion (Insulin Pump) ( 2.2 ): o Refer to the insulin infusion pump user manual to see if NOVOLOG can be used. Use in accordance with the insulin pump instructions for use. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 , 6.3 )].",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN DETEMIR",
      "brand": "LEVEMIR",
      "description": "Insulin detemir has a molecular formula of C 267 H 402 O 76 N 64 S 6 and a molecular weight of 5.917 kDa. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH. Levemir Chemical Structure.jpg",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na\u00efve patients with type 1 diabetes. Recommended Starting Dosage in Patients with Type 2 Diabetes The recommended starting dose of LEVEMIR in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist is 10 units (or 0.1 units/kg to 0.2 units/kg) given once daily in the evening or divided into a twice daily regimen.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN GLARGINE",
      "brand": "BASAGLAR Tempo Pen",
      "description": "Insulin glargine has the following structural formula: BASAGLAR (insulin glargine) injection is a sterile clear and colorless aqueous solution for subcutaneous use. The 3 mL BASAGLAR prefilled pen presentations contain the following inactive ingredients per mL: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (content adjusted to provide 30 mcg zinc ion), and Water for Injection, USP. BASAGLAR has a pH of approximately 4.",
      "dosage": "Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6 )] . During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring [see Warnings and Precautions ( 5.2 )] . The recommended starting dose of BASAGLAR in patients with type 2 diabetes is 0.2 units/kg or up to 10 units once daily.",
      "stock": 100,
      "route": "SUBCUTANEOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "INSULIN LISPRO",
      "brand": "ADMELOG",
      "description": "11 DESCRIPTION Insulin lispro is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli . Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.",
      "dosage": "Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Administer ADMELOG by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ISOSORBIDE MONONITRATE",
      "brand": "ISOSORBIDE MONONITRATE",
      "description": "Each tablet, for oral administration, contains either 30 mg, 60 mg or 120 mg of isosorbide mononitrate in an extended-release formulation. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, diethyl phthalate, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, talc and titanium dioxide. The chemical name for ISMN is 1,4:3,6-dianhydro-,D-glucitol 5-nitrate; the compound has the following structural formula: ISMN is a white, crystalline, odorless compound which is stable in air and in solution, has a melting point of about 90\u00b0C, and an optical rotation of +144\u00b0 (2% in water, 20\u00b0C).",
      "dosage": "After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. The daily dose of isosorbide mononitrate extended-release tablets should be taken in the morning on arising. Isosorbide mononitrate extended-release tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LAMOTRIGINE",
      "brand": "Lamotrigine",
      "description": "11 DESCRIPTION Lamotrigine, USP an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine\u2019s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine orally disintegrating tablets are formulated using in-house technologies designed to mask the bitter taste of lamotrigine and achieve a rapid dissolution profile.",
      "dosage": "Adjustments to the Maintenance Dose of Lamotrigine in Women Taking Estrogen-Containing Oral Contraceptives: (1) Taking Estrogen-Containing Oral Contraceptives : In women not taking carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], the maintenance dose of lamotrigine orally disintegrating tablets will in most cases need to be increased by as much as 2-fold over the recommended target maintenance dose to maintain a consistent lamotrigine plasma level. For women taking lamotrigine orally disintegrating tablets in addition to carbamazepine, phenytoin, phenobarbital, primidone, or other drugs such as rifampin and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir that induce lamotrigine glucuronidation [see Drug Interactions (7) , Clinical Pharmacology (12.3) ], no adjustment to the dose of lamotrigine orally disintegrating tablets should be necessary. Conversion from Adjunctive Therapy with Valproate to Monotherapy with Lamotrigine Orally Disintegrating Tablets in Patients Aged 16 Years and Older with Epilepsy Lamotrigine Orally Disintegrating Tablets Valproate Step 1 Achieve a dose of 200 mg/day according to guidelines in Table 1.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LANSOPRAZOLE",
      "brand": "Lansoprazole",
      "description": "Lansoprazole has the following structure: Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166\u00b0C. The degradation half-life of the drug substance in aqueous solution at 25\u00b0C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. Lansoprazole Delayed-Release Capsules, USP are supplied in delayed-release capsules for oral administration.The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule.",
      "dosage": "For patients who have difficulty swallowing capsules, Lansoprazole delayed-release capsules can be opened and administered orally or via a nasogastric tube in the soft foods or liquids specified below. Administration of Lansoprazole delayed-release capsules in foods or liquids other than those discussed below have not been studied clinically and therefore are not recommended. 5.To ensure complete delivery of the dose, rinse the glass with two or more volumes of juice and swallow the contents immediately.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVETIRACETAM",
      "brand": "Levetiracetam Extended-release",
      "description": "11 DESCRIPTION Levetiracetam Extended-release Tablets USP is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration. It has the following structural formula: Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane.",
      "dosage": "2 DOSAGE & ADMINISTRATION Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 ) 2.1 Recommended Dosing Levetiracetam extended-release tablet is administered once daily. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LEVOTHYROXINE, LIOTHYRONINE",
      "brand": "NP Thyroid 120",
      "description": "NP Thyroid \u00ae (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. They contain both tetraiodothyronine sodium (T 4 levothyroxine) and triiodothyronine sodium (T 3 liothyronine) providing 38 mcg levothyroxine (T 4 ) and 9 mcg liothyronine (T 3 ) per grain of thyroid. The inactive ingredients are calcium stearate, dextrose (agglomerated) and mineral oil.",
      "dosage": "DOSAGE AND ADMINISTRATION The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings. The usual starting dose is 30 mg NP Thyroid \u00ae , with increments of 15 mg every 2 to 3 weeks. This is the basis for the thyroid suppression test and is used as an aid in the diagnosis of patients with signs of mild hyperthyroidism in whom base line laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves ophthalmopathy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "brand": "Lisinopril and Hydrochlorothiazide",
      "description": "DESCRIPTION Lisinopril and hydrochlorothiazide tablets combine an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. 2H 2 O and its structural formula is: Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 and its structural formula is: Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.73, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.",
      "dosage": "In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. Therapy with any combination of lisinopril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but addition of lisinopril in clinical trials blunted the hypokalemia normally seen with diuretics. Dose Titration Guided by Clinical Effect A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochlorothiazide monotherapy may be switched to lisinopril and hydrochlorothiazide tablets 10-12.5 or lisinopril and hydrochlorothiazide tablets 20-12.5.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LORAZEPAM",
      "brand": "Lorazepam",
      "description": "DESCRIPTION Lorazepam USP, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3\u2011-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one: It is a nearly white powder almost insoluble in water. Each lorazepam tablet, USP to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam, USP. The inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.",
      "dosage": "DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOSARTAN POTASSIUM",
      "brand": "Losartan Potassium",
      "description": "11 DESCRIPTION Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype. Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is: Losartan potassium, USP is white to off-white powder with a molecular weight of 461.01. It is freely soluble in water; soluble in isopropyl alcohol; slightly soluble in acetonitrile.",
      "dosage": "Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. 2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of losartan potassium tablets once daily. The suspension should be refrigerated at 2 to 8\u00b0C (36 to 46\u00b0F) and can be stored for up to 4 weeks.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LOVASTATIN",
      "brand": "Lovastatin",
      "description": "This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. 404.55 C 24 H 36 O 5 M.W. Lovastatin Tablets USP, 40 mg also contain D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, and FD&C Yellow #6 Aluminum Lake.",
      "dosage": "Patients requiring reductions in LDL-C of 20% or more to achieve their goal (see INDICATIONS AND USAGE ) should be started on 20 mg/day of lovastatin tablets. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelines 4 , CLINICAL PHARMACOLOGY , and INDICATIONS AND USAGE ). Patients requiring reductions in LDL-C of 20% or more to achieve their goal should be started on 20 mg/day of lovastatin tablets.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "LURASIDONE HYDROCHLORIDE",
      "brand": "Lurasidone Hydrochloride",
      "description": "11 DESCRIPTION Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Its chemical name is (3a R ,4 S ,7 R ,7a S )-2-{(1 R ,2 R )-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-\u00adylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2 H -isoindole-1,3-dione hydrochloride. Its molecular formula is C 28 H 36 N 4 O 2 S\u00b7HCl and its molecular weight is 529.14.",
      "dosage": "Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [ see Clinical Studies (14.1) ]. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [ see Clinical Studies ( 14.1 ) ]. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4) , Drug Interactions (7.1) ] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MELOXICAM",
      "brand": "Meloxicam",
      "description": "11 DESCRIPTION Meloxicam, is a nonsteroidal anti-inflammatory drug (NSAID). Its empirical formula is C 14 H 13 N 3 O 4 S 2 and it has the following structural formula: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. Meloxicam tablets USP are available as tablets for oral administration containing 7.5 mg or 15 mg meloxicam.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals ( 2.1 ) OA ( 2.2 ) and RA (2.3): Starting dose: 7.5 mg once daily Dose may be increased to 15 mg once daily JRA ( 2.4 ): 7.5 mg once daily in children \u226560 kg Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same ( 2.6 ) 2.1 General Dosing Instructions Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MEMANTINE",
      "brand": "Memantine hydrochloride",
      "description": "11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHADONE HYDROCHLORIDE",
      "brand": "Methadone Hydrochloride",
      "description": "DESCRIPTION Methadone Hydrochloride Oral Concentrate, USP, contains methadone, an opiate agonist, and is available as a cherry flavored liquid concentrate for oral administration. It is present in methadone hydrochloride oral concentrate as the racemic mixture. Other ingredients of Methadone Hydrochloride Oral Concentrate, USP (Dye-Free, Sugar-Free, Unflavored): citric acid anhydrous, purified water, and sodium benzoate.",
      "dosage": "Titration and Maintenance Treatment of Opioid Dependence Patients in maintenance treatment should be titrated to a dose at which opioid symptoms are prevented for 24 hours, drug hunger or craving is reduced, the euphoric effects of self-administered opioids are blocked or attenuated, and the patient is tolerant to the sedative effects of methadone. Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms ( see DRUG ABUSE AND DEPENDENCE ). When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHOCARBAMOL",
      "brand": "Methocarbamol",
      "description": "The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.",
      "dosage": "Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets, USP: 750 mg \u2013 Adults: Initial dosage: 2 tablets q.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METHYLPHENIDATE HYDROCHLORIDE",
      "brand": "Methylphenidate Hydrochloride (LA)",
      "description": "Each Methylphenidate Hydrochloride Extended-Release Capsule contains pellets, with half the dose as immediate-release and half as delayed-release, thus providing an immediate release of methylphenidate and a second delayed release of methylphenidate. The active substance in Methylphenidate Hydrochloride Extended-Release Capsules is methyl \u03b1-phenyl-2-piperidineacetate hydrochloride. Its structural formula is as follows: M.W.",
      "dosage": "The drug and applesauce mixture should not be stored for future use. 2.3 Patients Currently Using Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets The recommended dose of methylphenidate hydrochloride extended-release capsules for patients currently taking methylphenidate hydrochloride tablets twice daily or methylphenidate hydrochloride extended-release (SR) is provided below. Table 1: Recommended Dose Conversion from Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Previous Methylphenidate Hydrochloride Tablets or Methylphenidate Hydrochloride Extended-Release Tablets Dose Recommended Methylphenidate Hydrochloride Extended-Release Capsules Dose 5 mg methylphenidate hydrochloride tablets twice daily 10 mg once daily 10 mg methylphenidate hydrochloride tablets twice daily or 20 mg methylphenidate hydrochloride extended-release tablets 20 mg once daily 15 mg methylphenidate hydrochloride tablets twice daily 30 mg once daily 20 mg methylphenidate hydrochloride tablets twice daily or 40 mg methylphenidate hydrochloride extended-release tablets 40 mg once daily 30 mg methylphenidate hydrochloride tablets twice daily or 60 mg methylphenidate hydrochloride extended-release tablets 60 mg once daily 2.4 Switching from other Methylphenidate Products If switching from other methylphenidate products, discontinue that treatment, and titrate with methylphenidate hydrochloride extended-release capsules using the titration schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METOPROLOL TARTRATE",
      "brand": "Metoprolol Tartrate",
      "description": "11 DESCRIPTION Metoprolol tartrate tablets, USP contain metoprolol tartrate, a selective beta 1 -adrenoreceptor blocking agent. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Metoprolol tartrate tablets, USP are available as 25 mg, 50 mg and 100 mg tablets for oral administration containing 25 mg, 50 mg and 100 mg metoprolol tartrate, respectively.",
      "dosage": "The effective dosage range of metoprolol tartrate tablets is 100 mg to 450 mg per day. The effective dosage range of metoprolol tartrate tablets is 100 to 400 mg per day. In patients who tolerate the full intravenous dose, initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for 48 hours.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "METRONIDAZOLE",
      "brand": "Metronidazole",
      "description": "DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure",
      "dosage": "There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. 500 mg for a 70-kg adult). If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY ).",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MIRTAZAPINE",
      "brand": "Mirtazapine",
      "description": "Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the molecular formula of C 17 H 19 N 3 . The structural formula is the following and it is the racemic mixture: Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.",
      "dosage": "If patients do not have an adequate response to the initial 15 mg dose, increase the dose up to a maximum of 45 mg per day. Conversely, a decrease in dosage of mirtazapine tablets may be needed if the CYP3A inducer is discontinued [see Drug Interactions (7) ]. Conversely, an increase in dosage of mirtazapine tablets may be needed if the CYP3A4 inhibitor is discontinued [see Drug Interactions (7) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "MONTELUKAST SODIUM",
      "brand": "Montelukast Sodium",
      "description": "DESCRIPTION Montelukast sodium, the active ingredient in montelukast sodium tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT 1 receptor. Montelukast sodium is described chemically as [ R-(E) ]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt. Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: croscarmellose sodium, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and titanium dioxide.",
      "dosage": "Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4). The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: For adults and adolescents 15 years of age and older: one 10-mg tablet. 2.4 Asthma and Allergic Rhinitis Patients with both asthma and allergic rhinitis should take only one montelukast sodium dose daily in the evening.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NAPROXEN",
      "brand": "Naproxen",
      "description": "11 DESCRIPTION Naproxen Tablets, USP and Naproxen Sodium Tablets, USP are nonsteroidal anti-inflammatory drugs available as follows: Naproxen Tablets, USP are available as follows for oral administration: 250 mg: circular, light orange colored, flat, uncoated tablets, engraved with \u2018G\u2019 and \u201832\u2019 on either side of a break line on one side and \u2018250\u2019 on the other side. The inactive ingredients are croscarmellose sodium, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Naproxen, USP and naproxen sodium, USP have the following structures, respectively: Naproxen Naproxen Sodium Naproxen, USP is a white to off-white crystalline powder.",
      "dosage": "Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. Table 1: Recommended dosages for naproxen tablets and naproxen sodium tablets Naproxen tablets 250 mg (one half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one half tablet) 550 mg (naproxen 500 mg with 50 mg sodium) twice daily During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. 2.4 Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen sodium tablets is 550 mg followed by 550 mg every 12 hours or 275 mg (one half of a 550 mg tablet) every 6 to 8 hours as required.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NITROGLYCERIN",
      "brand": "NITROGLYCERIN",
      "description": "11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula",
      "dosage": "2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. ( 2 ) \u2022 May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.",
      "stock": 100,
      "route": "SUBLINGUAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "NORTRIPTYLINE HYDROCHLORIDE",
      "brand": "Nortriptyline Hydrochloride",
      "description": "DESCRIPTION Nortriptyline Hydrochloride, USP is 1-propanamine, 3-(10,11-dihydro-5 H -dibenzo[ a,d ]cyclohepten-5-ylidene)- N -methyl, hydrochloride. The structural formula is as follows: C19H21N\u2219HCl MW = 299.84 Each capsule, for oral administration, contains nortriptyline hydrochloride equivalent to 10 mg, 25 mg, 50 mg, and 75 mg of nortriptyline hydrochloride USP. In addition, each capsule contains the following inactive ingredients: black iron oxide, colloidal silicon dioxide, D&C Yellow #10 (aluminum lake), D&C Yellow #10, FD&C Blue #1 (aluminum lake), FD&C Blue #2 (aluminum lake), FD&C Green #3 (10, 50 and 75 mg only), FD&C Red #40 (aluminum lake), gelatin, I.M.S. 74 OP, magnesium stearate, pregelatinized corn starch, shellac, sodium lauryl sulfate and titanium dioxide.",
      "dosage": "Usual Adult Dose 25 mg three or four times daily; dosage should begin at a low level and be increased as required. Use of Nortriptyline Hydrochloride With Other MAOIs, Such as Linezolid or Methylene Blue Do not start nortriptyline hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, nortriptyline hydrochloride should be stopped promptly, and linezolid or intravenous methylene blue can be administered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OMEPRAZOLE",
      "brand": "Omeprazole",
      "description": "",
      "dosage": "Directions for adults 18 years of age and older this product is to be used once a day (every 24 hours), every day for 14 days it may take 1 to 4 days for full effect; some people get complete relief of symptoms within 24 hours 14-Day Course of Treatment swallow 1 tablet with a glass of water before eating in the morning take every day for 14 days do not take more than 1 tablet a day do not use for more than 14 days unless directed by your doctor swallow whole. Do not chew or crush tablets Repeated 14-Day Courses (if needed) you may repeat a 14-day course every 4 months do not take for more than 14 days or more often than every 4 months unless directed by a doctor children under 18 years of age: ask a doctor. Heartburn in children may sometimes be caused by a serious condition.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ONDANSETRON HYDROCHLORIDE",
      "brand": "ondansetron hydrochloride",
      "description": "11 DESCRIPTION The active ingredient in ondansetron tablets is ondansetron hydrochloride as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (\u00b1) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose 2910(5cP) (for the 4 mg and 16 mg tablets only) and hypromellose 2910 (6cP) (for the 8 mg and 24 mg tablets only), iron oxide red and iron oxide black (for the 24 mg tablet only), iron oxide yellow (for the 8 mg and 24 mg tablets only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, and titanium dioxide.",
      "dosage": "2 DOSAGE AND ADMINISTRATION See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. For single high-dose fraction radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy. For daily fractionated radiotherapy to the abdomen : 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8 mg doses every 8 hours after the first dose for each day radiotherapy is given.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "OXYCODONE HYDROCHLORIDE",
      "brand": "Oxycodone Hydrochloride",
      "description": "Each tablet for oral administration contains 15 mg, or 30 mg, of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. The 15 mg and 30 mg tablets contain the equivalent of 13.5 mg and 27.0 mg, respectively, of oxycodone free base.",
      "dosage": "If a decision is made to discontinue the use of non-opioid analgesic, it may be necessary to titrate the dose of oxycodone hydrochloride in response to the level of analgesia and adverse effects afforded by the dosing regimen. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking oxycodone hydrochloride, there are a variety of factors that should be considered, including the dose of oxycodone hydrochloride the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PANTOPRAZOLE SODIUM INJECTION",
      "brand": "PANTOPRAZOLE SODIUM",
      "description": "11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The reconstituted solution of pantoprazole sodium for injection is in the pH range of 9.0 to 10.5.",
      "dosage": "( 2.3 , 2.4 ) 2.1 Recommended Dosage for GERD Associated with a History of EE Adult Patients The recommended adult dosage of pantoprazole sodium for injection is 40 mg once daily by intravenous injection (over at least 2 minutes) or intravenous infusion (for 15 minutes) for up to 10 days. (pantoprazole sodium) for Injection. (pantoprazole sodium) for Injection.",
      "stock": 100,
      "route": "INTRAVENOUS",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PAROXETINE HYDROCHLORIDE HEMIHYDRATE",
      "brand": "Paroxetine",
      "description": "11 DESCRIPTION Paroxetine tablets contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R -(4'-fluorophenyl)-3 S -[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 \u2022HCl\u20221/2H 2 O. The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120 o to 138 o C and a solubility of 5.4 mg/mL in water.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. Table 1: Recommended Daily Dosage of Paroxetine Tablets in Patients with MDD, OCD, PD, and PTSD Indication Starting Dose Maximum Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg 2.3 Recommended Dosage for SAD and GAD SAD The starting and recommended dosage in patients with SAD is 20 mg daily. In addition, at least 14 days must elapse after stopping paroxetine tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )] .",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PENICILLIN G BENZATHINE",
      "brand": "BICILLIN L-A",
      "description": "Description Bicillin L-A (penicillin G benzathine injectable suspension) is available for deep intramuscular injection. Its chemical structure is as follows: Bicillin L-A contains penicillin G benzathine in aqueous suspension with sodium citrate buffer and, as w/v, approximately 0.65% sodium citrate, 0.59% povidone, 0.54% carboxymethylcellulose sodium, 0.53% lecithin, 0.12% methylparaben, and 0.013% propylparaben. Bicillin L-A contains approximately 0.11 mEq of sodium per 600,000 units of penicillin G (approximately 2.59 mg of sodium per 600,000 units of penicillin G).",
      "dosage": "DOSAGE AND ADMINISTRATION Streptococcal (Group A) Upper Respiratory Infections (for example, pharyngitis) Adults\u2014a single injection of 1,200,000 units; older pediatric patients\u2014a single injection of 900,000 units; infants and pediatric patients under 60 lbs.\u2014300,000 to 600,000 units. Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PHENYTOIN SODIUM",
      "brand": "Phenytoin Sodium",
      "description": "11 DESCRIPTION Phenytoin Sodium Injection, USP is a sterile solution containing in each mL phenytoin sodium 50 mg, propylene glycol 0.4 mL and alcohol 0.1 mL in Water for Injection. pH 10.0-12.3; sodium hydroxide added, if needed, for pH adjustment. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring.",
      "dosage": "( 2.2 , 2.3 ) 2.1 General Dosing Information Because of the increased risk of adverse cardiovascular reactions associated with rapid administration, intravenous administration should not exceed 50 mg per minute in adults. Treatment with Phenytoin Sodium Injection can be initiated either with a loading dose or an infusion: Loading Dose: A loading dose of parenteral Phenytoin Sodium Injection should be injected slowly, not exceeding 50 mg per minute in adults and 1 to 3 mg/kg/min (or 50 mg per minute, whichever is slower) in pediatric patients. Infusion: For infusion administration, parenteral Phenytoin Sodium Injection should be diluted in normal saline with the final concentration of phenytoin sodium in the solution no less than 5 mg/mL.",
      "stock": 100,
      "route": "INTRAMUSCULAR",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PIOGLITAZONE HYDROCHLORIDE",
      "brand": "PIOGLITAZONE HYDROCHLORIDE",
      "description": "11 DESCRIPTION Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone. Pioglitazone [(\u00b1)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo .",
      "dosage": "(2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. The recommended starting dose for patients without congestive heart failure is 15 mg or 30 mg once daily. The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREDNISONE",
      "brand": "PredniSONE",
      "description": "DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.",
      "dosage": "Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient\u2019s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient\u2019s condition. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PREGABALIN",
      "brand": "PREGABALIN",
      "description": "The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with pregelatinized starch and talc as inactive ingredients. In addition, the orange & red capsule shells contain red iron oxide.",
      "dosage": "( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. 2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of pregabalin capsules is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of pregabalin have been shown to be dose-related.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROMETHAZINE HYDROCHLORIDE",
      "brand": "PROMETHAZINE HYDROCHLORIDE",
      "description": "DESCRIPTION Each 12.5 mg promethazine hydrochloride tablet for oral administration contains 12.5 mg promethazine hydrochloride. In addition, 50 mg tablet contains FD&C Red #40 and 12.5 mg tablet contains FD&C Yellow #6. Promethazine hydrochloride is a racemic compound; the empirical formula is C 17 H 20 N 2 S\u2022HCl and its molecular weight is 320.88.",
      "dosage": "The average effective dose of promethazine hydrochloride tablets, USP for the active therapy of nausea and vomiting in children or adults is 25 mg. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. Pre- and Postoperative Use Promethazine hydrochloride tablets, USP in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "PROPRANOLOL HYDROCHLORIDE",
      "brand": "Propranolol Hydrochloride",
      "description": "Propranolol Hydrochloride Tablets, USP are available as tablets for oral administration containing either 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride, USP. 6 aluminum lake (10 mg and 80 mg), D&C Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no.",
      "dosage": "Hypertension The usual initial dosage is 40 mg propranolol hydrochloride twice daily, whether used alone or added to a diuretic. Angina Pectoris Total daily doses of 80 mg to 320 mg propranolol hydrochloride, when administered orally, twice a day, three times a day, or four times a day, have been shown to increase exercise tolerance and to reduce ischemic changes in the ECG. The recommended daily dosage is 180 mg to 240 mg propranolol hydrochloride per day in divided doses.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "QUETIAPINE FUMARATE",
      "brand": "Quetiapine Fumarate",
      "description": "It is present in tablets as the fumarate salt. Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets. The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.",
      "dosage": "Further adjustments can be made in increments of 25 to 50 mg twice a day, in intervals of not less than 2 days. The dose should be increased daily in increments of 25 mg/day - 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RABEPRAZOLE SODIUM",
      "brand": "Rabeprazole sodium",
      "description": "11 DESCRIPTION The active ingredient in rabeprazole sodium delayed-release tablets is rabeprazole sodium hydrate, USP, which is a proton pump inhibitor. The stability of rabeprazole sodium hydrate, USP is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is: Rabeprazole sodium hydrate, USP is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium hydrate, USP.",
      "dosage": "The use of rabeprazole sodium delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Table 1: Recommended Dosage and Duration of Rabeprazole Sodium Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older * For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Indication Dosage of Rabeprazole Sodium delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks* Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks** Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks*** Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies ( 14.5 )] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow rabeprazole sodium delayed-release tablets whole.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RANITIDINE",
      "brand": "Ranitidine",
      "description": "",
      "dosage": "Directions adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "RISPERIDONE",
      "brand": "RISPERIDONE",
      "description": "11 DESCRIPTION Risperidone tablets, USP contain risperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The structural formula is: Risperidone USP is a white to slightly beige powder. Tablets of 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg also contain talc and titanium dioxide.",
      "dosage": "Maintenance Therapy While it is unknown how long a patient with schizophrenia should remain on risperidone tablets, the effectiveness of risperidone tablets 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years [see Clinical Studies (14.1) ] . After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ROSUVASTATIN CALCIUM",
      "brand": "Rosuvastatin Calcium",
      "description": "11 DESCRIPTION Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The empirical formula for rosuvastatin calcium is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white or almost white, hygroscopic powder that is slightly soluble in water, freely soluble in methylene chloride, practically insoluble in ethanol.",
      "dosage": "( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin tablets is 5 to 40 mg orally once daily.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SERTRALINE HYDROCHLORIDE",
      "brand": "Sertraline Hydrochloride",
      "description": "DESCRIPTION Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride, USP has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.",
      "dosage": "While a relationship between dose and effect has not been established for OCD, patients were dosed in a range of 25-200 mg/day in the clinical trials demonstrating the effectiveness of Sertraline hydrochloride for pediatric patients (6-17 years) with OCD. Systematic evaluation of continuing Sertraline hydrochloride for periods of up to 28 weeks in patients with OCD and Panic Disorder who have responded while taking Sertraline hydrochloride during initial treatment phases of 24 to 52 weeks of treatment at a dose range of 50-200 mg/day has demonstrated a benefit of such maintenance treatment (see Clinical Trials under CLINICAL PHARMACOLOGY ). Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SILDENAFIL CITRATE",
      "brand": "SILDENAFIL CITRATE",
      "description": "11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration.",
      "dosage": "However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "EZETIMIBE AND SIMVASTATIN",
      "brand": "Ezetimibe and Simvastatin",
      "description": "11 DESCRIPTION Ezetimibe and simvastatin tablets contain ezetimibe USP, a selective inhibitor of intestinal cholesterol and related phytosterol absorption, and simvastatin USP, an HMG-CoA reductase inhibitor. The chemical name of ezetimibe, USP is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. formula 1 formula 2",
      "dosage": "The maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. The ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to adult patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions ( 5.1 )]. Do not exceed ezetimibe and simvastatin tablets 10 mg/20 mg once daily (or 10 mg/40 mg once daily for patients who have previously taken ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically while taking lomitapide) [see Dosage and Administration ( 2.1 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SITAGLIPTIN AND METFORMIN HYDROCHLORIDE",
      "brand": "ZITUVIMET",
      "description": "Sitagliptin is present in ZITUVIMET tablets in the form of sitagliptin free base. Sitagliptin free base is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3 (trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine with an empirical formula of C 16 H 15 F 6 N 5 O and a molecular weight of 407.31. In addition, the film coating contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.",
      "dosage": "( 2.1 ) The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.2 ) \u25cb Do not use in patients with eGFR below 30 mL/min/1.73 m 2 \u25cb ZITUVIMET is not recommended in patients with eGFR between 30 and less than 45 mL/min/1.73 m 2 . 2.3 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue ZITUVIMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SPIRONOLACTONE",
      "brand": "Spironolactone",
      "description": "11 DESCRIPTION Spironolactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, USP 17hydroxy-7\u03b1-mercapto-3-oxo-17\u03b1-pregn-4-ene-21-carboxylic acid \u03b3-lactone acetate, which has the following structural formula: Spironolactone, USP is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, croscarmellose sodium, peppermint flavor, hypromellose, iron oxide, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, polyvinyl alcohol, povidone, talc, titanium dioxide, and triacetin. The 50 mg tablet also contains D&C yellow # 10 and FD&C yellow #6.",
      "dosage": "2.2 Treatment of Heart Failure In patients with serum potassium \u2264 5.0 mEq/L and eGFR > 50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily. 2.5 Treatment of Primary Hyperaldosteronism Administer spironolactone tablets in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, spironolactone tablets can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TAMSULOSIN HYDROCHLORIDE",
      "brand": "Tamsulosin Hydrochloride",
      "description": "11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The molecular formula of tamsulosin hydrochloride is C 20 H 28 N 2 O 5 S \u2022 HCl.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TEMAZEPAM",
      "brand": "Temazepam",
      "description": "DESCRIPTION Temazepam, USP is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 ClN 2 O 2 MW = 300.74 Temazepam, USP is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam capsules USP, 7.5 mg, 15 mg, 22.5 mg, and 30 mg, are for oral administration.",
      "dosage": "DOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. Discontinuation or Dosage Reduction of Temazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TERAZOSIN HYDROCHLORIDE",
      "brand": "Terazosin",
      "description": "DESCRIPTION Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name,molecular formula and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.C 19 H 26 ClN 5 O 4 Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 423.93. Each capsule, for oral administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as terazosin hydrochlolde. In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pregelatinized starch.",
      "dosage": "DOSAGE AND ADMINISTRATION If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen. The following is a guide to its administration: Initial Dose 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TIZANIDINE",
      "brand": "tizanidine",
      "description": "11 DESCRIPTION Tizanidine Tablets, USP contains tizanidine hydrochloride as the active ingredient, which is a central alpha 2 -adrenergic agonist. Its chemical name is 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole monohydrochloride. It has a molecular formula of C 9 H 8 CIN 5 S\u00b7HCl and a molecular weight of 290.17.",
      "dosage": "( 2.1 ) Recommended starting dose: 2 mg by mouth every 6 to 8 hours, as needed, up to a maximum of 3 doses in 24 hours ( 2.2 ) Dosage can be increased by 2 mg to 4 mg per dose every 1 to 4 days; maximum total daily dosage is 36 mg ( 2.2 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. 2.5 Discontinuation of Tizanidine Tablets When discontinuing tizanidine tablets, particularly in patients who have been receiving high doses for long periods or who may be on concomitant treatment with narcotics, decrease the dosage by 2 mg to 4 mg per day to minimize the risk of withdrawal adverse reactions [see Drug Abuse and Dependence ( 9.3 )]. If these situations occur, monitor patients for therapeutic effect or adverse reactions [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TOPIRAMATE",
      "brand": "topiramate",
      "description": "11 DESCRIPTION Topiramate, USP is a sulfamate-substituted monosaccharide. Topiramate tablets, USP are available as 25 mg, 50 mg, 100 mg, and 200 mg round shaped tablets for oral administration. Its saturated solution has a pH of 6.3.",
      "dosage": "Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to 9 Years of Age Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12 to 22 200 300 23 to 31 200 350 32 to 38 250 350 Greater than 38 250 400 * Administered in two equally divided doses 2.2 Dosing in Adjunctive Therapy Epilepsy Adults (17 Years of Age and Older) The recommended total daily dose of topiramate tablets as adjunctive therapy in adults with partial-onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Topiramate tablets should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAMADOL HYDROCHLORIDE",
      "brand": "TRAMADOL HYDROCHLORIDE",
      "description": "The chemical name is (\u00b1) cis -2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride extended-release tablets, USP contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation.",
      "dosage": "2.5 Safe Reduction or Discontinuation of Tramadol Hydrochloride Extended-Release Tablets Do not abruptly discontinue tramadol hydrochloride extended-release tablets in patients who may be physically dependent on opioids. When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking tramadol hydrochloride extended-release tablets, there are a variety of factors that should be considered, including the total daily dose of opioid (including tramadol hydrochloride extended-release tablets) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time, and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "TRAZODONE HYDROCHLORIDE",
      "brand": "Trazodone Hydrochloride",
      "description": "11 DESCRIPTION Trazodone hydrochloride is a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- 1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white to off-white, crystalline powder which is sparingly soluble in chloroform and in water.",
      "dosage": "The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. In addition, at least 14 days must elapse after stopping trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "SACUBITRIL AND VALSARTAN",
      "brand": "ENTRESTO",
      "description": "Its molecular mass is 957.99 g/mol and its schematic structural formula is: ENTRESTO is available as film-coated tablets for oral administration, containing 24 mg of sacubitril and 26 mg of valsartan; 49 mg of sacubitril and 51 mg of valsartan; and 97 mg of sacubitril and 103 mg of valsartan. The film-coat inactive ingredients are hypromellose, iron oxide red (E172), polyethylene glycol 4000, talc, and titanium dioxide (E171). The film-coat for the 49 mg of sacubitril and 51 mg of valsartan tablet contains iron oxide yellow (E172).",
      "dosage": "2 DOSAGE AND ADMINISTRATION The recommended starting dosage for adults is 49 mg/51 mg orally twice daily. Table 1: Recommended Dose and Titration for Pediatric Patients Using Tablets \u2020 Use of the oral suspension or oral pellets (see Table 2) is recommended in these patients. Use in patients with severe hepatic impairment is not recommended.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VENLAFAXINE",
      "brand": "Venlafaxine",
      "description": "DESCRIPTION Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. Each venlafaxine tablet, USP intended for oral administration contains venlafaxine hydrochloride equivalent to 25 mg or 37.5 mg or 50 mg or 75 mg or 100 mg of venlafaxine. Structured formula for venlafaxine",
      "dosage": "When treating pregnant women with venlafaxine tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. Dosage for Elderly Patients No dose adjustment is recommended for elderly patients on the basis of age. In some cases, a patient already receiving therapy with venlafaxine tablets may require urgent treatment with linezolid or intravenous methylene blue.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "VERAPAMIL HYDROCHLORIDE",
      "brand": "Verapamil Hydrochloride",
      "description": "DESCRIPTION Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. The structural formula of verapamil hydrochloride is: Benzeneacetonitrile, \u03b1-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-\u03b1-(1-methylethyl) hydrochloride. Verapamil hydrochloride is an almost white, crystalline powder, practically free of odor, with a bitter taste.",
      "dosage": "Angina: Clinical trials show that the usual dose is 80 mg to 120 mg three times a day. However, 40 mg three times a day may be warranted in patients who may have an increased response to verapamil (e.g., decreased hepatic function, elderly, etc.). In general, maximum effects for any given dosage will be apparent during the first 48 hours of therapy.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "WARFARIN SODIUM",
      "brand": "Warfarin Sodium",
      "description": "11 DESCRIPTION Warfarin sodium tablets, USP contain warfarin sodium, an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. 40 aluminum lake, and D&C yellow no. 10 aluminum lake and FD&C yellow no.",
      "dosage": "The duration of treatment is based on the indication as follows: For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended. Dosing Recommendations without Consideration of Genotype If the patient\u2019s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg once daily. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets therapy with heparin for 4 to 5 days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZALEPLON",
      "brand": "zaleplon",
      "description": "Its molecular formula is C 17 H 15 N 5 O, and its molecular weight is 305.34. Zaleplon capsules USP contain zaleplon as the active ingredient. The 5 mg capsules also contain FD&C yellow #5.",
      "dosage": "Although the risk of certain adverse events associated with the use of zaleplon capsules appears to be dose dependent, the 20 mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of a lower dose. Zaleplon capsules are not recommended for use in patients with severe hepatic impairment. Zaleplon capsules have not been adequately studied in patients with severe renal impairment.",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLPIDEM TARTRATE",
      "brand": "Zolpidem",
      "description": "11 DESCRIPTION Zolpidem Tartrate Tablets, USP contains Zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. It has the following structure: Zolpidem Tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. Opadry II (pink) contains hypromellose, FD&C Red no.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 ) 2.1 Dosage in Adults Use the lowest effective dose for the patient. The total dose of Zolpidem Tartrate Tablets should not exceed 10 mg once daily immediately before bedtime. The recommended dose of Zolpidem Tartrate Tablets in these patients is 5 mg once daily immediately before bedtime [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.5 )].",
      "stock": 100,
      "route": "ORAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.drug",
    "fields": {
      "name": "ZOLMITRIPTAN",
      "brand": "Zolmitriptan",
      "description": "11 DESCRIPTION ZOLMITRIPTAN NASAL SPRAY contains zolmitriptan, which is a selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: The empirical formula is C 16 H 21 N 3 O 2 , representing a molecular weight of 287.36. The osmolarity of ZOLMITRIPTAN NASAL SPRAY for 2.5 mg is 360 to 420 mOsmol, and for 5 mg is 420 to 470 mOsmol.",
      "dosage": "2 DOSAGE AND ADMINISTRATION Recommended starting dose: 2.5 mg (2.1) Maximum single dose: 5 mg (2.1) May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period (2.1) 2.1 Dosing Information The recommended starting dose for ZOLMITRIPTAN NASAL SPRAY in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to ZOLMITRIPTAN NASAL SPRAY may vary, the dose should be adjusted on an individual basis. The safety of ZOLMITRIPTAN NASAL SPRAY in the treatment of an average of more than four headaches in a 30-day period has not been established. 2.3 Dosing in Patients taking Cimetidine If ZOLMITRIPTAN NASAL SPRAY is co-administered with cimetidine, limit the maximum single dose of ZOLMITRIPTAN NASAL SPRAY to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)] .",
      "stock": 100,
      "route": "NASAL",
      "resupply_pending": 0,
      "pharmacy_id": 6,
      "status": "in_stock"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-10-16 18:04:10.597485",
      "expiration_date": "2026-08-06",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 0,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 70,
      "prescribed_on": "2025-10-16 19:43:03.319963",
      "expiration_date": "2025-10-31",
      "medicine_id": 727,
      "patient_id": 298,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 70,
      "prescribed_on": "2025-10-16 19:46:33.913082",
      "expiration_date": "2025-10-31",
      "medicine_id": 727,
      "patient_id": 297,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 70,
      "prescribed_on": "2025-10-16 19:49:25.722859",
      "expiration_date": "2025-10-31",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 15,
      "prescribed_on": "2025-10-20 09:52:18.287396",
      "expiration_date": "2026-08-06",
      "medicine_id": 729,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 0,
      "refill_pending": 0,
      "refilled_on": "2025-10-22 11:41:26.498404"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 15,
      "prescribed_on": "2025-10-21 11:08:32.929118",
      "expiration_date": "2026-08-06",
      "medicine_id": 730,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 0,
      "refill_pending": 0,
      "refilled_on": "2025-10-22 12:12:30.446231"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-10-21 11:21:11.741154",
      "expiration_date": "2026-08-05",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 1,
      "refill_pending": 1,
      "refilled_on": "2025-10-22 11:01:39.144974"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-10-23 17:43:48.656027",
      "expiration_date": "2026-08-06",
      "medicine_id": 737,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 0,
      "refill_pending": 0,
      "refilled_on": "2025-10-23 18:17:39.686834"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-10-23 18:59:36.078800",
      "expiration_date": "2026-08-05",
      "medicine_id": 777,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2025-10-23 19:00:18.669327"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-10-23 19:04:25.457683",
      "expiration_date": "2025-10-23",
      "medicine_id": 733,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-10-23 19:47:00.426195",
      "expiration_date": "2025-10-31",
      "medicine_id": 731,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 60,
      "prescribed_on": "2025-10-23 19:47:22.725637",
      "expiration_date": "2025-10-31",
      "medicine_id": 731,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 0,
      "prescribed_on": "2025-10-23 20:18:12.303088",
      "expiration_date": "2025-10-31",
      "medicine_id": 844,
      "patient_id": 300,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 1,
      "prescribed_on": "2025-10-25 17:18:27.760163",
      "expiration_date": "2025-10-31",
      "medicine_id": 744,
      "patient_id": 300,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 1,
      "prescribed_on": "2025-10-25 17:18:48.866290",
      "expiration_date": "2025-10-31",
      "medicine_id": 729,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-03 11:38:11.577604",
      "expiration_date": "2025-11-26",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-03 11:40:43.123029",
      "expiration_date": "2025-11-27",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-03 12:01:04.584141",
      "expiration_date": "2025-11-25",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 70,
      "prescribed_on": "2025-11-03 12:09:08.929943",
      "expiration_date": "2025-11-27",
      "medicine_id": 729,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 30,
      "prescribed_on": "2025-11-03 12:09:34.309335",
      "expiration_date": "2025-11-27",
      "medicine_id": 729,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-03 12:42:03.851423",
      "expiration_date": "2025-11-30",
      "medicine_id": 730,
      "patient_id": 295,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-03 20:33:49.760032",
      "expiration_date": "2025-11-17",
      "medicine_id": 728,
      "patient_id": 282,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-03 20:34:24.805814",
      "expiration_date": "2025-11-27",
      "medicine_id": 728,
      "patient_id": 286,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 50,
      "prescribed_on": "2025-11-03 21:02:37.683552",
      "expiration_date": "2025-11-27",
      "medicine_id": 737,
      "patient_id": 298,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-03 21:16:19.754423",
      "expiration_date": "2025-11-30",
      "medicine_id": 740,
      "patient_id": 289,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-04 11:27:01.397286",
      "expiration_date": "2025-11-27",
      "medicine_id": 815,
      "patient_id": 297,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-04 11:35:51.592463",
      "expiration_date": "2025-11-26",
      "medicine_id": 733,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-04 11:57:43.149056",
      "expiration_date": "2025-11-19",
      "medicine_id": 736,
      "patient_id": 289,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-04 12:33:42.197295",
      "expiration_date": "2025-11-28",
      "medicine_id": 734,
      "patient_id": 286,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-04 20:19:36.643545",
      "expiration_date": "2025-11-25",
      "medicine_id": 844,
      "patient_id": 291,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-05 10:57:41.497505",
      "expiration_date": "2025-11-13",
      "medicine_id": 808,
      "patient_id": 290,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-05 17:00:34.618397",
      "expiration_date": "2026-08-05",
      "medicine_id": 732,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2025-11-05 17:01:38.021035"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-11-05 21:47:44.575050",
      "expiration_date": "2025-11-29",
      "medicine_id": 757,
      "patient_id": 300,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-11-05 22:05:54.606958",
      "expiration_date": "2025-11-29",
      "medicine_id": 757,
      "patient_id": 295,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-05 22:07:21.977227",
      "expiration_date": "2025-11-28",
      "medicine_id": 757,
      "patient_id": 295,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-05 22:53:40.848469",
      "expiration_date": "2025-11-25",
      "medicine_id": 744,
      "patient_id": 297,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-05 23:00:26.919030",
      "expiration_date": "2025-11-28",
      "medicine_id": 742,
      "patient_id": 297,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 11:01:07.147202",
      "expiration_date": "2025-11-27",
      "medicine_id": 750,
      "patient_id": 285,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 11:10:08.292779",
      "expiration_date": "2025-11-18",
      "medicine_id": 741,
      "patient_id": 285,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-06 11:13:40.704892",
      "expiration_date": "2025-11-20",
      "medicine_id": 741,
      "patient_id": 298,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 11:42:46.130722",
      "expiration_date": "2025-11-27",
      "medicine_id": 814,
      "patient_id": 282,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-06 11:48:02.187554",
      "expiration_date": "2025-11-26",
      "medicine_id": 814,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 12:07:31.568636",
      "expiration_date": "2025-11-26",
      "medicine_id": 758,
      "patient_id": 287,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 12:32:48.393523",
      "expiration_date": "2026-08-05",
      "medicine_id": 734,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2025-11-06 12:34:48.288828"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-06 12:33:16.883822",
      "expiration_date": "2025-11-27",
      "medicine_id": 734,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 90,
      "prescribed_on": "2025-11-06 17:47:15.073729",
      "expiration_date": "2026-08-05",
      "medicine_id": 753,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 1,
      "refill_pending": 1,
      "refilled_on": "2025-11-06 17:50:57.317286"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-06 17:48:21.479590",
      "expiration_date": "2026-08-05",
      "medicine_id": 753,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 1,
      "refill_pending": 1,
      "refilled_on": "2025-11-06 17:52:40.746651"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-11-06 18:06:41.923921",
      "expiration_date": "2026-08-05",
      "medicine_id": 744,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2025-11-26 21:26:39.345958"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-26 19:25:24.054518",
      "expiration_date": "2025-12-03",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 10,
      "prescribed_on": "2025-11-26 20:45:43.058453",
      "expiration_date": "2025-11-28",
      "medicine_id": 844,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-12-01 11:21:12.449436",
      "expiration_date": "2025-12-26",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-12-01 11:30:37.881703",
      "expiration_date": "2025-12-31",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-12-01 11:36:42.827486",
      "expiration_date": "2025-12-10",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-12-01 11:37:41.548331",
      "expiration_date": "2026-08-20",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2025-12-01 12:39:12.322399"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-12-01 11:50:34.773682",
      "expiration_date": "2025-12-24",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 100,
      "prescribed_on": "2025-12-01 11:56:09.132822",
      "expiration_date": "2025-12-25",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 80,
      "prescribed_on": "2025-12-01 12:12:52.865324",
      "expiration_date": "2026-01-01",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 20,
      "prescribed_on": "2025-12-01 12:13:22.805939",
      "expiration_date": "2026-08-06",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 0,
      "refill_pending": 0,
      "refilled_on": "2025-12-01 12:39:39.598209"
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 1,
      "prescribed_on": "2025-12-24 13:41:33.100090",
      "expiration_date": "2025-12-23",
      "medicine_id": 740,
      "patient_id": 286,
      "prescribed_by_id": 46,
      "refills_left": 2,
      "refill_pending": 1,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 25,
      "prescribed_on": "2026-01-03 11:38:19.753949",
      "expiration_date": "2026-01-20",
      "medicine_id": 727,
      "patient_id": 1,
      "prescribed_by_id": 46,
      "refills_left": 3,
      "refill_pending": 0,
      "refilled_on": null
    }
  },
  {
    "model": "pharmacy.prescription",
    "fields": {
      "quantity": 25,
      "prescribed_on": "2026-01-03 11:43:14.132899",
      "expiration_date": "2026-01-29",
      "medicine_id": 606,
      "patient_id": 345,
      "prescribed_by_id": 43,
      "refills_left": 2,
      "refill_pending": 0,
      "refilled_on": "2026-01-03 11:44:00.510771"
    }
  },
  {
    "model": "patients.medicationreminder",
    "fields": {
      "frequency": 2,
      "prescription_id": 16,
      "user_id": 1,
      "is_active": 0,
      "start_date": "2025-12-15",
      "day_amount": 1,
      "remaining_days": 1,
      "is_archived": 1,
      "restoration_time": "2025-12-15 20:07:20.990550"
    }
  },
  {
    "model": "patients.medicationreminder",
    "fields": {
      "frequency": 2,
      "prescription_id": 51,
      "user_id": 1,
      "is_active": 0,
      "start_date": "2025-12-15",
      "day_amount": 2,
      "remaining_days": 2,
      "is_archived": 1,
      "restoration_time": "2025-12-15 20:23:28.250634"
    }
  },
  {
    "model": "patients.medicationreminder",
    "fields": {
      "frequency": 1,
      "prescription_id": 56,
      "user_id": 1,
      "is_active": 0,
      "start_date": "2025-12-15",
      "day_amount": 2,
      "remaining_days": 2,
      "is_archived": 1,
      "restoration_time": "2025-12-15 20:02:48.864839"
    }
  },
  {
    "model": "patients.medicationreminder",
    "fields": {
      "frequency": 1,
      "prescription_id": 20,
      "user_id": 1,
      "is_active": 0,
      "start_date": "2025-12-13",
      "day_amount": 1,
      "remaining_days": 1,
      "is_archived": 1,
      "restoration_time": "2025-12-13 15:58:02.550150"
    }
  },
  {
    "model": "patients.medicationreminder",
    "fields": {
      "frequency": 2,
      "prescription_id": 70,
      "user_id": 345,
      "is_active": 1,
      "start_date": "2026-01-05",
      "day_amount": 2,
      "remaining_days": 2,
      "is_archived": 0,
      "restoration_time": "2026-01-05 20:07:43.676673"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "15:50:00",
      "reminder_id": 11,
      "is_active": 1,
      "task_id": "a8d658e7-88c1-4567-8d63-6aae3ffd381e"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "07:41:00",
      "reminder_id": 11,
      "is_active": 1,
      "task_id": "0fb79fd4-db77-4cbc-948c-ee40299e779f"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "15:49:00",
      "reminder_id": 12,
      "is_active": 1,
      "task_id": "8daddfc8-be65-4d75-b568-6afd4ff1e95d"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "16:36:00",
      "reminder_id": 12,
      "is_active": 1,
      "task_id": "4861fffc-7fa2-4071-b0b1-06ebc80e69e9"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "16:12:00",
      "reminder_id": 13,
      "is_active": 1,
      "task_id": "a6bd8bb1-a3d6-4ad2-99a5-328c225d307f"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "16:20:00",
      "reminder_id": 14,
      "is_active": 1,
      "task_id": "00bfcd12-4bd1-4d22-a597-26e0d94d3c6b"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "15:31:00",
      "reminder_id": 15,
      "is_active": 1,
      "task_id": "7458f41e-ac50-443b-961a-7e8a5411bb67"
    }
  },
  {
    "model": "patients.remindertime",
    "fields": {
      "time": "15:32:00",
      "reminder_id": 15,
      "is_active": 1,
      "task_id": "42194a67-1e42-481a-8536-e6dee5038818"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-01 22:12:00.077091",
      "last_updated": "2025-12-01 22:12:00.077158"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-24 13:41:33.113900",
      "last_updated": "2025-12-24 13:41:33.113951"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-26 00:58:53.149582",
      "last_updated": "2025-12-26 00:58:53.149679"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-26 20:46:56.954859",
      "last_updated": "2025-12-26 20:46:56.954922"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-26 20:47:29.756282",
      "last_updated": "2025-12-26 20:47:29.756360"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2025-12-31 22:58:48.982818",
      "last_updated": "2025-12-31 22:58:48.982871"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2026-01-03 11:38:19.764971",
      "last_updated": "2026-01-03 11:38:19.765035"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2026-01-03 11:43:14.141527",
      "last_updated": "2026-01-03 11:43:14.141567"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2026-01-03 11:44:00.525227",
      "last_updated": "2026-01-03 11:44:00.525299"
    }
  },
  {
    "model": "accounts.thread",
    "fields": {
      "created_at": "2026-01-03 11:57:18.831294",
      "last_updated": "2026-01-03 11:57:18.831343"
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 122,
      "customaccount_id": 17
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 122,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 122,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 122,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 122,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 417
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 420
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 123,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 365
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 420
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 124,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 367
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 420
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 125,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 364
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 420
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 126,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 127,
      "customaccount_id": 428
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 127,
      "customaccount_id": 47
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 127,
      "customaccount_id": 371
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 127,
      "customaccount_id": 372
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 127,
      "customaccount_id": 373
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 417
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 420
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 23
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 348
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 349
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 128,
      "customaccount_id": 350
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 417
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 325
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 326
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 327
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 14
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 129,
      "customaccount_id": 16
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 130,
      "customaccount_id": 417
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 130,
      "customaccount_id": 428
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 428
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 14
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 16
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 325
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 326
    }
  },
  {
    "model": "accounts.thread_participant",
    "fields": {
      "thread_id": 131,
      "customaccount_id": 327
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello can i get a prescripption for acetaminophen?",
      "timestamp": "2025-12-01 22:12:12.977746",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "qR",
      "timestamp": "2025-12-01 22:15:41.508363",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "WaR",
      "timestamp": "2025-12-01 22:15:52.559358",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "supp",
      "timestamp": "2025-12-01 22:15:56.035310",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-01 22:15:59.286423",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "no way",
      "timestamp": "2025-12-01 22:16:07.601304",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2025-12-22 19:21:17.860158",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2025-12-22 19:35:37.246733",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "wow",
      "timestamp": "2025-12-22 19:41:52.492813",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yes",
      "timestamp": "2025-12-22 19:45:47.937623",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "huh",
      "timestamp": "2025-12-22 19:46:13.823163",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "whioa",
      "timestamp": "2025-12-22 19:52:45.952649",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2025-12-22 19:59:53.639611",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "i do get the message appended and notification but its only after i refresh",
      "timestamp": "2025-12-22 20:00:46.856264",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-22 20:03:29.437989",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-22 20:09:34.920261",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-22 20:27:14.227637",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-22 20:31:35.938702",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hey",
      "timestamp": "2025-12-22 20:35:21.725003",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yi",
      "timestamp": "2025-12-22 20:36:51.979219",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2025-12-22 20:37:39.582443",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2025-12-22 20:57:31.034169",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2025-12-22 21:02:18.961302",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2025-12-22 21:02:23.545047",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "sup",
      "timestamp": "2025-12-22 21:02:31.250897",
      "recipient_id": null,
      "sender_id": 348,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hey",
      "timestamp": "2025-12-22 21:02:36.197593",
      "recipient_id": null,
      "sender_id": 17,
      "thread_id": 122,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "You have a new prescription.",
      "timestamp": "2025-12-24 13:41:33.125996",
      "recipient_id": null,
      "sender_id": 417,
      "thread_id": 123,
      "link": "/pharmacy/patient_profile/286#prescription-68",
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2026-01-02 22:17:04.549674",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "wassup",
      "timestamp": "2026-01-02 22:19:42.376419",
      "recipient_id": null,
      "sender_id": 47,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "nothing much",
      "timestamp": "2026-01-02 22:20:12.742370",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "wassup",
      "timestamp": "2026-01-02 22:20:40.985816",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2026-01-02 22:24:10.386641",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2026-01-02 22:24:38.317523",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hey",
      "timestamp": "2026-01-02 22:25:09.448475",
      "recipient_id": null,
      "sender_id": 47,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "whoa",
      "timestamp": "2026-01-02 22:28:33.659839",
      "recipient_id": null,
      "sender_id": 47,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "wow",
      "timestamp": "2026-01-02 22:28:50.839590",
      "recipient_id": null,
      "sender_id": 47,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "hello",
      "timestamp": "2026-01-02 22:36:29.502039",
      "recipient_id": null,
      "sender_id": 47,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "You have a new prescription.",
      "timestamp": "2026-01-03 11:38:19.772777",
      "recipient_id": null,
      "sender_id": 417,
      "thread_id": 128,
      "link": "/pharmacy/patient_profile/1#prescription-69",
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "You have a new prescription.",
      "timestamp": "2026-01-03 11:43:14.147573",
      "recipient_id": null,
      "sender_id": 417,
      "thread_id": 129,
      "link": "/pharmacy/patient_profile/345#prescription-70",
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo teresa",
      "timestamp": "2026-01-03 11:45:11.376825",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 127,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo teresa",
      "timestamp": "2026-01-03 11:57:27.354599",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2026-01-03 11:57:36.380274",
      "recipient_id": null,
      "sender_id": 325,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "wassup",
      "timestamp": "2026-01-03 11:57:40.968117",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "chillin",
      "timestamp": "2026-01-03 11:58:00.723893",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2026-01-03 11:58:06.383499",
      "recipient_id": null,
      "sender_id": 325,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what the helly",
      "timestamp": "2026-01-03 11:58:20.876057",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2026-01-03 12:02:16.711595",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "what",
      "timestamp": "2026-01-03 12:02:26.289431",
      "recipient_id": null,
      "sender_id": 325,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "sup",
      "timestamp": "2026-01-03 12:02:39.098093",
      "recipient_id": null,
      "sender_id": 325,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "yo",
      "timestamp": "2026-01-03 12:02:53.157532",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "no way",
      "timestamp": "2026-01-03 12:03:02.968136",
      "recipient_id": null,
      "sender_id": 325,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.message",
    "fields": {
      "content": "sup",
      "timestamp": "2026-01-03 12:03:07.854069",
      "recipient_id": null,
      "sender_id": 428,
      "thread_id": 131,
      "link": null,
      "refill_fulfilled": null,
      "prescription_id": null,
      "drug_id": null,
      "resupply_fulfilled": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-01 12:38:09.387352",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "A refill request from Justin Jackson has been sent.",
      "drug_id": null,
      "link": "/pharmacy/refill_prescriptions/65",
      "prescription_id": 65
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-01 12:38:09.433594",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "A refill request from Justin Jackson has been sent.",
      "drug_id": null,
      "link": "/pharmacy/refill_prescriptions/65",
      "prescription_id": 65
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 376,
      "time": "2025-12-01 22:12:12.998044",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 376,
      "time": "2025-12-01 22:12:13.002870",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 377,
      "time": "2025-12-01 22:15:41.527582",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 377,
      "time": "2025-12-01 22:15:41.533288",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 378,
      "time": "2025-12-01 22:15:52.580347",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 378,
      "time": "2025-12-01 22:15:52.586543",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 379,
      "time": "2025-12-01 22:15:56.053374",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 379,
      "time": "2025-12-01 22:15:56.058712",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 380,
      "time": "2025-12-01 22:15:59.309406",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 380,
      "time": "2025-12-01 22:15:59.316164",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 381,
      "time": "2025-12-01 22:16:07.620146",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 381,
      "time": "2025-12-01 22:16:07.625031",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 382,
      "time": "2025-12-22 19:21:17.895076",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 382,
      "time": "2025-12-22 19:21:17.903307",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 383,
      "time": "2025-12-22 19:35:37.269555",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 383,
      "time": "2025-12-22 19:35:37.276411",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 384,
      "time": "2025-12-22 19:41:52.524905",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 384,
      "time": "2025-12-22 19:41:52.531382",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 385,
      "time": "2025-12-22 19:45:47.971036",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 385,
      "time": "2025-12-22 19:45:47.978665",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 386,
      "time": "2025-12-22 19:46:13.856671",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 386,
      "time": "2025-12-22 19:46:13.868225",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 387,
      "time": "2025-12-22 19:52:45.982089",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 387,
      "time": "2025-12-22 19:52:45.995197",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 388,
      "time": "2025-12-22 19:59:53.671995",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 388,
      "time": "2025-12-22 19:59:53.681128",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 389,
      "time": "2025-12-22 20:00:46.884470",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 389,
      "time": "2025-12-22 20:00:46.890115",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 390,
      "time": "2025-12-22 20:03:29.471447",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 390,
      "time": "2025-12-22 20:03:29.478510",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 391,
      "time": "2025-12-22 20:09:34.956614",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 391,
      "time": "2025-12-22 20:09:34.965626",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 392,
      "time": "2025-12-22 20:27:14.260455",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 392,
      "time": "2025-12-22 20:27:14.273596",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 393,
      "time": "2025-12-22 20:31:35.965751",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 393,
      "time": "2025-12-22 20:31:35.979205",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 394,
      "time": "2025-12-22 20:35:21.762342",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 394,
      "time": "2025-12-22 20:35:21.767459",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 395,
      "time": "2025-12-22 20:36:52.014950",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 395,
      "time": "2025-12-22 20:36:52.020920",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 396,
      "time": "2025-12-22 20:37:39.614608",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 396,
      "time": "2025-12-22 20:37:39.620208",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 397,
      "time": "2025-12-22 20:57:31.071079",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 397,
      "time": "2025-12-22 20:57:31.078130",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 398,
      "time": "2025-12-22 21:02:19.001110",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 398,
      "time": "2025-12-22 21:02:19.006687",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 399,
      "time": "2025-12-22 21:02:23.573603",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 399,
      "time": "2025-12-22 21:02:23.582465",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 400,
      "time": "2025-12-22 21:02:31.276474",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 400,
      "time": "2025-12-22 21:02:31.286769",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 401,
      "time": "2025-12-22 21:02:36.221154",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 401,
      "time": "2025-12-22 21:02:36.227940",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 402,
      "time": "2025-12-24 13:41:33.133835",
      "user_id": 356,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-29 19:28:58.481954",
      "user_id": 23,
      "reminder_id": null,
      "is_read": 1,
      "content": "A resupply of CETIRIZINE HYDROCHLORIDE TABLETS (cetirizine hydrochloride) has been requested due to low inventory.",
      "drug_id": 750,
      "link": "/pharmacy/drug_detail/750",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-30 21:58:57.776100",
      "user_id": 23,
      "reminder_id": null,
      "is_read": 1,
      "content": "A resupply of ALLOPURINOL (Allopurinol) has been requested due to low inventory.",
      "drug_id": 731,
      "link": "/pharmacy/drug_detail/731",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:07.093374",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "ALLOPURINOL (Allopurinol) has been resupplied.",
      "drug_id": 731,
      "link": "/pharmacy/drug_detail/731",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:07.100540",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "ALLOPURINOL (Allopurinol) has been resupplied.",
      "drug_id": 731,
      "link": "/pharmacy/drug_detail/731",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:07.104806",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "ALLOPURINOL (Allopurinol) has been resupplied.",
      "drug_id": 731,
      "link": "/pharmacy/drug_detail/731",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:07.108823",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "ALLOPURINOL (Allopurinol) has been resupplied.",
      "drug_id": 731,
      "link": "/pharmacy/drug_detail/731",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:38.932047",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "CETIRIZINE HYDROCHLORIDE TABLETS (cetirizine hydrochloride) has been resupplied.",
      "drug_id": 750,
      "link": "/pharmacy/drug_detail/750",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:38.939725",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "CETIRIZINE HYDROCHLORIDE TABLETS (cetirizine hydrochloride) has been resupplied.",
      "drug_id": 750,
      "link": "/pharmacy/drug_detail/750",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:38.944071",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "CETIRIZINE HYDROCHLORIDE TABLETS (cetirizine hydrochloride) has been resupplied.",
      "drug_id": 750,
      "link": "/pharmacy/drug_detail/750",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:38.947485",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "CETIRIZINE HYDROCHLORIDE TABLETS (cetirizine hydrochloride) has been resupplied.",
      "drug_id": 750,
      "link": "/pharmacy/drug_detail/750",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:58.432886",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "PANTOPRAZOLE SODIUM INJECTION (PANTOPRAZOLE SODIUM) has been resupplied.",
      "drug_id": 815,
      "link": "/pharmacy/drug_detail/815",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:58.437499",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "PANTOPRAZOLE SODIUM INJECTION (PANTOPRAZOLE SODIUM) has been resupplied.",
      "drug_id": 815,
      "link": "/pharmacy/drug_detail/815",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:58.443394",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "PANTOPRAZOLE SODIUM INJECTION (PANTOPRAZOLE SODIUM) has been resupplied.",
      "drug_id": 815,
      "link": "/pharmacy/drug_detail/815",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2025-12-31 21:02:58.447209",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "PANTOPRAZOLE SODIUM INJECTION (PANTOPRAZOLE SODIUM) has been resupplied.",
      "drug_id": 815,
      "link": "/pharmacy/drug_detail/815",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 403,
      "time": "2026-01-02 22:17:04.582780",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 403,
      "time": "2026-01-02 22:17:04.591679",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 403,
      "time": "2026-01-02 22:17:04.596729",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 404,
      "time": "2026-01-02 22:19:42.384648",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 404,
      "time": "2026-01-02 22:19:42.391893",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 404,
      "time": "2026-01-02 22:19:42.397609",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 405,
      "time": "2026-01-02 22:20:12.769013",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 405,
      "time": "2026-01-02 22:20:12.775991",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 405,
      "time": "2026-01-02 22:20:12.786131",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 406,
      "time": "2026-01-02 22:20:41.003723",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 406,
      "time": "2026-01-02 22:20:41.012966",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 406,
      "time": "2026-01-02 22:20:41.020040",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 407,
      "time": "2026-01-02 22:24:10.401994",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 407,
      "time": "2026-01-02 22:24:10.410974",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 407,
      "time": "2026-01-02 22:24:10.417518",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 408,
      "time": "2026-01-02 22:24:38.333937",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 408,
      "time": "2026-01-02 22:24:38.342341",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 408,
      "time": "2026-01-02 22:24:38.348880",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 409,
      "time": "2026-01-02 22:25:09.457722",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 409,
      "time": "2026-01-02 22:25:09.466880",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 409,
      "time": "2026-01-02 22:25:09.471929",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 410,
      "time": "2026-01-02 22:28:33.672986",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 410,
      "time": "2026-01-02 22:28:33.681801",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 410,
      "time": "2026-01-02 22:28:33.689578",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 411,
      "time": "2026-01-02 22:28:50.851466",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 411,
      "time": "2026-01-02 22:28:50.858256",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 411,
      "time": "2026-01-02 22:28:50.865822",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 412,
      "time": "2026-01-02 22:36:29.519213",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 412,
      "time": "2026-01-02 22:36:29.527506",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 412,
      "time": "2026-01-02 22:36:29.542823",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 413,
      "time": "2026-01-03 11:38:19.777053",
      "user_id": 17,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 414,
      "time": "2026-01-03 11:43:14.152519",
      "user_id": 428,
      "reminder_id": null,
      "is_read": 1,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-03 11:44:00.536933",
      "user_id": 428,
      "reminder_id": null,
      "is_read": 1,
      "content": "A refill request has been fulfilled and is ready for pick up.",
      "drug_id": null,
      "link": "/pharmacy/patient_profile/345#prescription-70",
      "prescription_id": 70
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 415,
      "time": "2026-01-03 11:45:11.391960",
      "user_id": 47,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 415,
      "time": "2026-01-03 11:45:11.407489",
      "user_id": 371,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 415,
      "time": "2026-01-03 11:45:11.415777",
      "user_id": 372,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 415,
      "time": "2026-01-03 11:45:11.423330",
      "user_id": 373,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 416,
      "time": "2026-01-03 11:57:27.364665",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 416,
      "time": "2026-01-03 11:57:27.373939",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 416,
      "time": "2026-01-03 11:57:27.390166",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 416,
      "time": "2026-01-03 11:57:27.397156",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 417,
      "time": "2026-01-03 11:57:36.391103",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 417,
      "time": "2026-01-03 11:57:36.399034",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 417,
      "time": "2026-01-03 11:57:36.407746",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 417,
      "time": "2026-01-03 11:57:36.414003",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 418,
      "time": "2026-01-03 11:57:40.980820",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 418,
      "time": "2026-01-03 11:57:40.986626",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 418,
      "time": "2026-01-03 11:57:41.008935",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 418,
      "time": "2026-01-03 11:57:41.017010",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 419,
      "time": "2026-01-03 11:58:00.734294",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 419,
      "time": "2026-01-03 11:58:00.744107",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 419,
      "time": "2026-01-03 11:58:00.759586",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 419,
      "time": "2026-01-03 11:58:00.766262",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 420,
      "time": "2026-01-03 11:58:06.395024",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 420,
      "time": "2026-01-03 11:58:06.403163",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 420,
      "time": "2026-01-03 11:58:06.410407",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 420,
      "time": "2026-01-03 11:58:06.416895",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 421,
      "time": "2026-01-03 11:58:20.888622",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 421,
      "time": "2026-01-03 11:58:20.900663",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 421,
      "time": "2026-01-03 11:58:20.916582",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 421,
      "time": "2026-01-03 11:58:20.922474",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 422,
      "time": "2026-01-03 12:02:16.725533",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 422,
      "time": "2026-01-03 12:02:16.746135",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 422,
      "time": "2026-01-03 12:02:16.781874",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 422,
      "time": "2026-01-03 12:02:16.797895",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 423,
      "time": "2026-01-03 12:02:26.300321",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 423,
      "time": "2026-01-03 12:02:26.328325",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 423,
      "time": "2026-01-03 12:02:26.358714",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 423,
      "time": "2026-01-03 12:02:26.391887",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 424,
      "time": "2026-01-03 12:02:39.110396",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 424,
      "time": "2026-01-03 12:02:39.133204",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 424,
      "time": "2026-01-03 12:02:39.154994",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 424,
      "time": "2026-01-03 12:02:39.177182",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 425,
      "time": "2026-01-03 12:02:53.173586",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 425,
      "time": "2026-01-03 12:02:53.195809",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 425,
      "time": "2026-01-03 12:02:53.336404",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 425,
      "time": "2026-01-03 12:02:53.399368",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 426,
      "time": "2026-01-03 12:03:02.982617",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 426,
      "time": "2026-01-03 12:03:03.001778",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 426,
      "time": "2026-01-03 12:03:03.014481",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 426,
      "time": "2026-01-03 12:03:03.044436",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 427,
      "time": "2026-01-03 12:03:07.862997",
      "user_id": 14,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 427,
      "time": "2026-01-03 12:03:07.888822",
      "user_id": 16,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 427,
      "time": "2026-01-03 12:03:07.935073",
      "user_id": 326,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": 427,
      "time": "2026-01-03 12:03:07.946534",
      "user_id": 327,
      "reminder_id": null,
      "is_read": 0,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:28:15.283841",
      "user_id": 428,
      "reminder_id": 15,
      "is_read": 1,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:32:00.031798",
      "user_id": 428,
      "reminder_id": 15,
      "is_read": 1,
      "content": null,
      "drug_id": null,
      "link": null,
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:53:41.362133",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "AMOXICILLIN (Amoxicillin) has been resupplied.",
      "drug_id": 733,
      "link": "/pharmacy/drug_detail/733",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:53:41.367216",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMOXICILLIN (Amoxicillin) has been resupplied.",
      "drug_id": 733,
      "link": "/pharmacy/drug_detail/733",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:53:41.370904",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMOXICILLIN (Amoxicillin) has been resupplied.",
      "drug_id": 733,
      "link": "/pharmacy/drug_detail/733",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:53:41.377106",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMOXICILLIN (Amoxicillin) has been resupplied.",
      "drug_id": 733,
      "link": "/pharmacy/drug_detail/733",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:54:36.541113",
      "user_id": 23,
      "reminder_id": null,
      "is_read": 1,
      "content": "A resupply of BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride XL) has been requested due to low inventory.",
      "drug_id": 742,
      "link": "/pharmacy/drug_detail/742",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:54:45.585305",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride XL) has been resupplied.",
      "drug_id": 742,
      "link": "/pharmacy/drug_detail/742",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:54:45.588552",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride XL) has been resupplied.",
      "drug_id": 742,
      "link": "/pharmacy/drug_detail/742",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:54:45.597310",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride XL) has been resupplied.",
      "drug_id": 742,
      "link": "/pharmacy/drug_detail/742",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 20:54:45.601571",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride XL) has been resupplied.",
      "drug_id": 742,
      "link": "/pharmacy/drug_detail/742",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 21:10:30.245684",
      "user_id": 23,
      "reminder_id": null,
      "is_read": 1,
      "content": "A resupply of AMLODIPINE BESYLATE (Amlodipine Besylate) has been requested due to low inventory.",
      "drug_id": 734,
      "link": "/pharmacy/drug_detail/734",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 21:10:44.943905",
      "user_id": 348,
      "reminder_id": null,
      "is_read": 1,
      "content": "AMLODIPINE BESYLATE (Amlodipine Besylate) has been resupplied.",
      "drug_id": 734,
      "link": "/pharmacy/drug_detail/734",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 21:10:45.034426",
      "user_id": 349,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMLODIPINE BESYLATE (Amlodipine Besylate) has been resupplied.",
      "drug_id": 734,
      "link": "/pharmacy/drug_detail/734",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 21:10:45.051360",
      "user_id": 350,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMLODIPINE BESYLATE (Amlodipine Besylate) has been resupplied.",
      "drug_id": 734,
      "link": "/pharmacy/drug_detail/734",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.notifications",
    "fields": {
      "message_id": null,
      "time": "2026-01-05 21:10:45.091443",
      "user_id": 420,
      "reminder_id": null,
      "is_read": 0,
      "content": "AMLODIPINE BESYLATE (Amlodipine Besylate) has been resupplied.",
      "drug_id": 734,
      "link": "/pharmacy/drug_detail/734",
      "prescription_id": null
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 376,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 376,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 376,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 376,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 377,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 377,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 377,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 377,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 378,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 378,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 378,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 378,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 379,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 379,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 379,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 379,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 380,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 380,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 380,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 380,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 381,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 381,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 381,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 381,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 382,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 382,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 382,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 382,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 383,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 383,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 383,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 383,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 384,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 384,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 384,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 384,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 385,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 385,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 385,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 385,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 386,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 386,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 386,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 386,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 387,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 387,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 387,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 387,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 388,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 388,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 388,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 388,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 389,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 389,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 389,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 389,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 390,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 390,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 390,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 390,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 391,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 391,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 391,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 391,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 392,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 392,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 392,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 392,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 393,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 393,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 393,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 393,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 394,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 394,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 394,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 394,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 395,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 395,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 395,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 395,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 396,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 396,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 396,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 396,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 397,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 397,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 397,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 397,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 398,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 398,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 398,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 398,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 399,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 399,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 399,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 399,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 400,
      "user_id": 17
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 400,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 400,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 400,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 401,
      "user_id": 23
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 401,
      "user_id": 348
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 401,
      "user_id": 349
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 401,
      "user_id": 350
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 403,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 403,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 403,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 403,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 404,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 404,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 404,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 404,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 405,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 405,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 405,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 405,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 406,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 406,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 406,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 406,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 407,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 407,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 407,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 407,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 408,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 408,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 408,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 408,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 409,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 409,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 409,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 409,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 410,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 410,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 410,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 410,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 411,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 411,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 411,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 411,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 412,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 412,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 412,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 412,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 415,
      "user_id": 47
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 415,
      "user_id": 371
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 415,
      "user_id": 372
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 415,
      "user_id": 373
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 416,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 416,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 416,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 416,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 416,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 417,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 417,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 417,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 417,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 417,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 418,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 418,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 418,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 418,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 418,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 419,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 419,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 419,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 419,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 419,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 420,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 420,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 420,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 420,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 420,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 421,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 421,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 421,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 421,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 421,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 422,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 422,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 422,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 422,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 422,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 423,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 423,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 423,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 423,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 423,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 424,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 424,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 424,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 424,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 424,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 425,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 425,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 425,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 425,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 425,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 426,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 426,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 426,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 426,
      "user_id": 327
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 426,
      "user_id": 428
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 427,
      "user_id": 14
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 427,
      "user_id": 16
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 1,
      "message_id": 427,
      "user_id": 325
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 427,
      "user_id": 326
    }
  },
  {
    "model": "accounts.readstatus",
    "fields": {
      "read": 0,
      "message_id": 427,
      "user_id": 327
    }
  }
]